Innovation Capital - Growing Tech Companies in Partnership with entrepreneurs

News

Silver Economie | 2018-09-20
Voluntis – First-half 2018: expanded and strengthened abilities to pursue future growth

•Developed direct commercial relationships with US payers and healthcare providers as well as extended collaboration with pharmaceutical industry

•Significant acceleration in investment to:

O strengthen organization and commercial capabilities, in line with increased interest in Voluntis’ digital therapeutics

O pursue technological developments

•H1 2018 revenue of €2.2 million, reflecting the evolution of the revenue structure, and EBIT of -€7.9 million due to an increase in staff costs

•Successful initial public offering, establishing cash of €28.6 million at end-June 2018

Paris, France, September 20, 2018, 5:40 pm CEST – Voluntis (Euronext Paris, ticker: VTX - ISIN: FR0004183960), a digital biotech specialized in digital therapeutics, announces its revenue and results for the first half of 2018, closed as of 30 June 2018.

Pierre Leurent, Chief Executive Officer of Voluntis, commented: "Following our successful IPO, which enabled us to finance our future development, we have continued to invest, in particular to strengthen our operational teams, mainly in the United States. In addition to strengthening our organization, we have also signed a contract with a US payer, a key stage in our development in this market, consolidated our product portfolio and extended our partnerships in oncology. In diabetes, we are planning to sign contracts with other payers in the United States and to expand our innovative solutions to other European countries."

Key events of the first half

•As it executes the strategy announced at the time of the IPO, Voluntis has focused its investments:

O In diabetes, to consolidate the organization and strengthen its commercial capabilities. During the first semester, these efforts led to:

O Signing an agreement in the United States with a payer, WellDyneRx, and continuing to deploy Insulia in healthcare centers.

O Extending the sales network through a distribution partnership with Monarch, thanks to its inpatient presence, and extending the product offering through a partnership with WellDoc, which aims to combine its coaching platform with Insulia.

O Launching a new version of Insulia, now available in Spanish and with enhanced user experience.

O Supporting the promotion of Insulia and Diabeo in France.

O Preparing the launch of Insulia in Canada, for which Insulia received regulatory clearance by Health Canada.

• In oncology, to continue technological, clinical and regulatory developments. Recently, Voluntis has:

O Strengthened its partnership with Roche, aiming to expand the indications covered by the Zemy app, and initiating a clinical study to evaluate the use of Zemy in breast cancer.

O Extended its agreement with AstraZeneca to implement a new clinical evaluation phase of the eCO digital therapy.

O Announced the publication of clinical results in the eCO (eCediranib-Olaparib) feasibility study, developed in partnership with AstraZeneca and the National Cancer Institute, in the Journal of Clinical Oncology (JCO®) Clinical Cancer Informatics.

O Enhanced its Theraxium Oncology digital platform, dedicated to cancer treatments.

H1 2018 revenue of €2.2 million, reflecting the evolution of Voluntis’ revenue structure, and EBIT of -€7.9 million due to an increase in staff costs

• Application of IFRS 15, the new revenue recognition standard: Voluntis has applied the standard since January 1, 2018, with no prior period restatement. A major evolution in the revenue recognition standard, the transition to this new model has nonetheless had a minor impact on the semester’s revenue, specifically less than €0.1 million.

• Variation in milestone payments: Voluntis reported first-half revenue of €2.2 million versus €5.7 million in first-half 2017, which benefited from €3.5 million of milestone payments compared with €0.1 million this year.

• Evolution of the revenue structure: The total revenue reduction reflects, per management expectations, the transition to a revenue model based more on recurring revenue from product sales and less on pre-launch revenue related to product development and approval. In the first semester, direct sales to payers and providers have yet to affect revenue.

In parallel, Voluntis continued to bolster its teams, particularly in the United States, to support the marketing and deployment of Insulia. The €1.5 million increase in operating expenses to €9.8 million was therefore due to growth in staff costs, which amounted to €6.7 million, including a €0.5 million impact related to IFRS 15. This new standard also takes into account the costs of contract execution with clients, of which a large part was recognized in personnel costs this semester.

On that basis, EBITDA came to -€7.0 million and EBIT to -€7.9 million.

After the IPO on Euronext Paris and the resulting capital increase, free cash amounted to €28.6 million on June 30, 2018 versus €1.8 million on December 31, 2017. Voluntis also issued a €4.0 million bond to Kreos during the period.

Outlook

Voluntis will continue to invest during the second half to support its growth.

Initiatives already underway include:

• Stepping up sales and marketing actions in the United States to extend the deployment of Insulia

• Finalizing the development of a proprietary multi-cancer solution in oncology

• Continuing to strengthen its teams by bringing in new skills, in particular new experts in the US market

Furthermore, the company foresees further strengthening its Board of Directors with additional well-known and deeply experienced US healthcare executives.

Medium-term targets unchanged

Voluntis has not changed its medium-term target of €50 million in revenue in 2021 after achieving breakeven at EBITDA level in 2020.

About Voluntis

Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to the patient and the care team that so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. These real-time recommendations are based on digitized clinical algorithms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics. These include Insulia and Diabeo in diabetes as well as eCO and ZEMY in oncology. Voluntis has long-standing partnerships with leading life science companies such as Roche, AstraZeneca, Sanofi and Onduo. Based out of Boston and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.

For further information: http://www.voluntis.com

Diabeo® is a registered trademark of Sanofi. Insulia® is a registered trademark of Voluntis.

www.voluntis.com/fr

Voluntis NewCap NewCap

Matthieu Plessis Marc Willaume / Tristan Nicolas Merigeau

CFO Roquet Montégon Media Relations

Phone nb : 01 41 38 39 20 Investor relations Phone nb.: 01 44 71 94 98

Email: Phone nb.: 01 44 71 94 94 Email: voluntis@newcap.eu

investisseurs@voluntis.com Email: voluntis@newcap.eu

Life Science | 2018-09-14
Kuros Biosciences to Host Key Opinion Leader Meeting on Establishing the New Gold Standard in Bone Regeneration

Schlieren (Zurich), Switzerland, September 14, 2018 – Kuros Biosciences, (SWX: KURN) a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration, announced today that it will host a Key Opinion Leader (KOL) luncheon on establishing the new gold standard in bone regeneration on Thursday, September 20 at the Hotel Richemond in Geneva, Switzerland.

The KOL event will feature presentations by KOLs John Sutcliffe MBChB FRCS(Ed) FRCS(SN), from the London Spine Clinic, and Andrew A. Sama, MD, from the Hospital for Special Surgery, Weill Cornell Medical College, who will discuss the scientific rationale of Kuros’s lead programs, Fibrin/PTH and MagnetOS, as well the overall treatment landscape in both Europe and the United States, and the commercial potential of Kuros’s innovative portfolio in bone regeneration.

Kuros’s CEO Joost de Bruijn will give a short investor presentation highlighting the Company’s progress to date and upcoming milestones.

John Sutcliffe is Triage Consultant Spinal Neurosurgeon & Lead Clinician, London Spine Clinic, having trained in Edinburgh and qualifying in 1983. He was appointed as a consultant neurosurgeon in 1993 and has since concentrated exclusively in the management of patients with spinal disorders. He pioneered the concept of the multi-disciplinary team approach to spinal disorders, setting up the London Spine Clinic in 1997, the first hospital of its kind in the UK at the time. He resigned from the NHS in 2000 but remains an Emeritus Consultant at Barts' and the London NHS Trust. As training director in the NHS and at the London Spine Clinic and London Clinic Hospital, Mr. Sutcliffe has trained many young spinal surgeons in his 25 years as a consultant.

Dr. Andrew Sama serves as Director of Spine Surgery Fellowship at Hospital for Special Surgery & Associate Professor of Clinical Orthopaedic Surgery, Orthopaedic Surgery, Weill Cornell Medical College. Dr. Andrew Sama specializes in the management of all traumatic, degenerative, and deformity-related conditions of the cervical, thoracic, and lumbosacral spine. He has received a number of research grants, including funding from the National Institutes of Health. Dr. Sama is involved in product development and has helped design several orthopedic implant devices. He has published articles in numerous peer-reviewed medical journals and co-edited a textbook titled "Lateral Access Minimally Invasive Spine Surgery." He is on the editorial board of Current Reviews in Musculoskeletal Medicine and serves as a reviewer for the journals Spine and Clinical Orthopaedics and Related Research.

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. A live webcast and replay will be accessible via the link here. If you would like to ask a question during the live Q&A, please submit your request via email.

For further information, please contact:

Kuros Biosciences AG LifeSci Advisors

Michael Grau Hans Herklots

Chief Financial Officer Media & Investors

Tel +41 44 733 47 47 +41 79 598 7149

michael.grau@kurosbio.com

hherklots@lifesciadvisors.com

About Kuros Biosciences AG

Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.com for additional information on Kuros, its science and product pipeline.

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

Life Science | 2018-09-05
Kuros Biosciences Reports Results for First Half 2018

(Corrected Version, including link to Half Year Report)

http://kuros.ch/uploads/Reports_and_Presentations/2018HY1.pdf

Financial highlights

 CHF 9.7 million cash at June 30

 Operating expenses decreased to CHF 6.0 million

Operational highlights

 First U.S. & European sales of MagnetOs

 Commercial rollout in the U.S. and Europe on track

 Preparation for Phase II clinical study of Fibrin-PTH in spine on track

Schlieren (Zurich), Switzerland,

September 5, 2018 – Kuros Biosciences has delivered on its targets in the first half of 2018, confirming its successful transition into a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration. Kuros has recorded first sales of MagnetOs in the U.S. and in Europe, and commercial rollout continues apace in both regions.

Joost de Bruijn, Chief Executive Officer, said: “We have successfully pursued the new course for Kuros in the first half of 2018, progressing on all fronts. We have realized the first sales from MagnetOs, an important milestone as we focus on the commercial opportunity of cutting-edge orthobiologics, and the commercial rollout is advancing on both sides of the Atlantic. Furthermore, we are driving forward the exciting clinical program with Fibrin-PTH in spinal fusion, which represents a huge commercial opportunity.

Financial position

Cash and cash equivalents (including financial assets and trade and other receivables) as per June 30, 2018, amounted to CHF 9.7 million, compared with CHF 21.4 million as per June 30, 2017.

Operating expenses decreased to CHF 6.0 million (first half 2017: CHF 7.5 million) primarily due to lower non-cash expenses in connection with share-based payments. Expenses for research and development of CHF 3.1 million (CHF 2.2 million in the first half 2017) are mainly external costs for the preparation of the Phase II study (spine indication) of fibrin PTH, personnel expenses and depreciation of tangible assets. Expenses for general and administrative of CHF 4.1 million contained costs for personnel and other expenses for maintenance and administration. Revenues amounted to CHF 0.3 million (first half 2017: CHF 0.5 million) and originated primarily from a milestone payment related to the agreement with Checkmate. Furthermore, the commercial rollout of MagnetOs recognized its first sales. Other income was CHF 1.1 million (first half 2017: CHF 1.5 million) and mainly consisted of proceeds from sub-lease agreements.

The net loss as per June 30, 2018 amounts to CHF 5.2 million, compared to CHF 7.0 million in the corresponding period in the first half of 2017. The primary reason for the substantial decrease of CHF 1.7 million are a substantial reduction in expenses for share-based payment and income tax effects.

Key figures H1 2018 H1 2017

In TCHF, IFRS

Revenue 274 534

Research and development (3,058) (2,211)

General and administrative (4,112) (6,777)

Other income 1,125 1,522

Net operating costs (6,045) (7,466)

Operating income/(loss) (5,787) (6,932)

Net financial income/(loss) (4) (247)

Net income/(loss) (5,247) (6,970)

Net income/(loss) per share (in CHF) (0.63) (1.11)

Cash and cash equivalents, financial

assets and trade and other receivables 9,650 21,417

Events after the reporting period

Kuros will issue 370,000 shares to former Xpand Biotechnology shareholders, a milestone related to the merger and triggered by the important CE mark certification in Europe for MagnetOs Putty, which today allows Kuros to commercialize MagnetOs Putty across Europe.

Outlook

Kuros’s products are advancing according to plan with MagnetOs Putty having received clearance for commercialization in the United States and recently having received CE mark in Europe followed by first commercial sales in the United States and Europe, in June 2018. Kuros is financed to initiate the commercialization of MagnetOs in the US and to prepare for the phase II clinical study of Fibrin-PTH in spine.

For further information, please contact:

Kuros Biosciences AG LifeSci Advisors

Michael Grau Hans Herklots

Chief Financial Officer Media & Investors

Tel +41 44 733 47 47 41 79 598 71 49

michael.grau@kurosbio.com

hherklots@lifesciadvisors.com

About Kuros Biosciences AG

Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kuros.ch for additional information on Kuros, its science and product pipeline.

Forward Looking Statements

Life Science | 2018-08-23
Kuros Biosciences appoints Pascal Longlade as Chief Medical Officer

Schlieren (Zurich), Switzerland, August 23, 2018 Kuros Biosciences AG (SIX: KURN) announced today the appointment of Pascal Longlade as Chief Medical Officer, effective September 1.

Pascal Longlade, MD, has more than 20 years international experience in clinical research and development with leading pharmaceutical, biotech and medical device companies, most recently as Director Medical Affairs, Head of Regulatory Affairs and Head of Pharmacovigilance at D&A Pharma in Paris. He replaces Virginia Jamieson, who has continued to work for Kuros as a consultant since her retirement in May.

“I’m delighted to welcome Pascal on board at Kuros and am very much looking forward to working with him,” said CEO Joost de Bruijn. “Pascal brings with him a wealth of experience and has previously built strong relationships with key opinion leaders, which will support the development of our clinical development pipeline and of the company.”

During his career, Pascal spent 10 years in clinical medicine and he has experience in managing large teams. He has previously served as Chief Medical Officer of Trophos SA, as Director of Clinical Research at Nicox SA and as Director Clinical Affairs EMEA at Abbott Vascular Devices. Mr. Longlade holds a MD from Lariboisière-Saint-Louis Medical School, Paris, France. He will be based at our site in Bilthoven, in the Netherlands.

“I am very excited to be joining Kuros at such an interesting point in its history, with several products going through clinical development and/or being launched in the US and EU as well as extensive opportunities to further develop the portfolio of innovative products in tissue repair and regeneration,” said Pascal Longlade.

For further information, please contact:

Kuros Biosciences AG LifeSci Advisors

Michael Grau Hans Herklots

Chief Financial Officer Media & Investors

Tel +41 44 733 47 47 +41 79 598 7149

michael.grau@kurosbio.com

hherklots@lifesciadvisors.com

About Kuros Biosciences AG

Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kuros.ch for additional information on Kuros, its science and product pipeline.

Forward Looking Statements

Silver Economie | 2018-08-16
Voluntis releases upgraded version of Insulia to improve user experience, including Spanish

Paris, France, August 16, 2018 – 6:00 pm CEST. Voluntis (Euronext Paris - ticker: VTX - ISIN Code: FR 0004183960), a digital biotech specialized in digital therapeutics, announces the release of an upgraded version of Insulia that improves user experience and makes Insulia available in Spanish.

“Over the past year, we’ve worked closely with the medical community and people with diabetes using Insulia to understand how we can further help meet their needs,” said Ellie Strock, Vice President of US Medical Affairs at Voluntis. “The beauty of digital therapeutics like Insulia is that we can use this feedback to continuously improve them, making insulin management ever easier.”

The addition of Spanish will allow providers and payers to expand the reach of Insulia for their at-risk diabetes population. The diabetes prevalence among Hispanics is 43% higher than the national average in the United States.1 In a recent study, 52% of Hispanics had poor glycemic control and were at higher risk for cardiometabolic abnormalities than non-Hispanic whites.2

Voluntis will be presenting the upgraded Insulia digital therapeutic at the AADE conference at booth #451 on the exhibition floor. In addition, attendees can come see our poster entitled “Smart Phones, Smart Coaches, Smart Patients: How to Use Digital Coaching in Type 2 Diabetes Management” (#P827).

About Insulia®

Insulia® provides automated basal insulin dose recommendations and coaching messages for people with type 2 diabetes while enabling the health care team to remotely monitor progress. A healthcare practitioner prescribes Insulia using their dedicated web portal and sets up the treatment plan rules that will adjust basal insulin dosing based on the person’s specific needs. The user then receives an activation code to get started with their personalized app. Once downloaded, the app uses blood glucose readings and any hypo symptoms to recommend doses in real-time. These are constantly updated using clinical algorithms built into the application. Data is automatically shared with the health care team, who can remotely monitor the patient’s progress toward their goal thanks to tailored notifications. This enables providers to deliver tailored telemedicine services, a practice increasingly supported by payers worldwide. Insulia is available for people using any brand of basal insulin including Lantus®, Levemir®, Toujeo®, Tresiba® (U-100) and Basaglar®.

For further information: http://www.insulia.com

About Voluntis

Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to the patient and the care team so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. These real-time recommendations are based on digitized clinical algorithms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics. These include Insulia® and Diabeo® in diabetes as well as eCO and ZEMY in oncology. Voluntis has long-standing partnerships with leading life science companies such as Roche, AstraZeneca, Sanofi and Onduo. Based out of Boston and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.

Insulia® is a registered trademark of Voluntis.

For further information: http://www.voluntis.com

1 https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf

2 http://www.diabetes.org/newsroom/press-releases/2014/diabetes-among-hispanics-all-are-not-equal.html

Silver Economie | 2018-07-31
Voluntis announces the launch of Theraxium Oncology, an innovative digital platform for symptom management

Paris, France, July 31, 2018 – Voluntis, a digital biotech specialized in digital therapeutics, announces the launch its Theraxium Oncology offer, a breakthrough technology that leverages digital therapeutics to empower patients so they can self-manage their symptoms, experienced when receiving cancer treatments, in coordination with care teams.

Theraxium Oncology takes advantage of over four years of research and development by Voluntis in partnership with life science partners and cancer institutes as well as user feedback from patients and multiple US cancer centers. It aims to deliver an improved patient journey by supporting self-management of symptoms and enhance decision-making and prioritization for care teams by providing them with patient-reported information. Initiated in ovarian and breast cancers, the new technology is designed to target the main cancer types, involving a wide range of treatments and mechanisms of action.

Symptom management, or supportive care, is essential to cancer care with a mean of 14 symptoms experienced per patient and frequency ranging between 11-91% depending on the symptom.[i] Treatment-related symptoms are known as the major reason for suboptimal adherence or treatment discontinuation.[ii] Severe symptoms often lead to unscheduled hospitalizations, since almost 80% of cancer hospitalizations are due to uncontrolled symptoms.[iii] Managing symptoms is therefore incredibly important for clinical practice, yet care teams are only partly aware of patient symptoms [iv] because they have few tools to monitor symptoms in a timely and effective manner and have limited time per patient.

“Providing and receiving supportive care can be a trying experience, both for patients and care teams,” says Romain Marmot, Chief Operations Officer at Voluntis. “Using evidence-based algorithms, digital therapeutics can empower patients to self-manage symptoms while allowing healthcare professionals to intervene at the right time, with the right data. The result is improved patient quality of life, reduced discontinuation rates and, ultimately increased survival.”

Voluntis’ technology combines a prescription mobile app and cloud-based solution for patients with a web portal for care teams. Patients enter symptom data in the app, either manually or by connecting to wireless sensors, to receive actionable recommendations personalized to their current condition. Leveraging embedded clinical algorithms, the app can help patients identify and qualify their symptoms, take treatment action in real time, gain knowledge about their disease and report their symptoms to their care teams.

Care teams follow the progress of their entire patient population in real-time from their desks thanks to their web portal, accessible without any download. Healthcare professionals can thus access the narrative of patient’s symptoms. This enables them to triage patients according to priority, take action to modify the treatment and coordinate better with all care team members and patients. The result is more responsive treatment management, improved patient engagement and care coordination, in view of improving both the quality and cost of care.

For more information about Theraxium Oncology: http://www.voluntis.com/oncology

About Voluntis

For further information: http://www.voluntis.com

[i] Stark et al. “The Symptom Experience of Patients with Cancer.” J Hosp Palliat Nurs. 2012 Jan-Feb; 14(1): 61–70.

[ii] Kidwell et al. “Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.” Cancer. 2014 Aug 15;120(16);2403-11.

[iii] Numico et al. “Hospital Admission of Cancer Patients: Avoidable Practice or Necessary Care?” PLoS One. 2015; 10(3): e0120827.

[iv] Rha et al. “Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms.” Support Care Cancer. 2016 Nov;24(11):4559-66.

Silver Economie | 2018-07-16
Publication des résultats de l’étude eCO dans la revue JCO® Clinical Cancer Informatics

Cambridge, MA, le 16 juillet 2018 à 18h00 – Voluntis (la « Société » ou « Voluntis » - mnémonique : VTX - ISIN : FR 0004183960), société spécialisée dans les logiciels thérapeutiques (digital therapeutics), annonce aujourd’hui que les résultats de l’étude eCO, la solution digitale d’accompagnement des femmes atteintes d’un cancer de l’ovaire, développée en partenariat avec AstraZeneca et le National Cancer Institute, ont été publiés dans la revue JCO® Clinical Cancer Informatics.

L’étude, publiée sous le titre « Technology APPlications: Use of digital health technology to enable drug development, » permettait d’étudier la faisabilité, la facilité d’utilisation et la satisfaction perçue des patientes utilisant eCO (eCediranib-Olaparib), une application mobile permettant d’assurer le suivi et la notification des effets secondaires chez les femmes atteintes d’un cancer de l’ovaire récidivant. La solution eCO a été spécifiquement conçue pour faciliter la prise en charge d’événements liés au traitement, tels que l’hypertension et la diarrhée, le plus souvent associés à l’arrêt du traitement, la nécessité d’un « congé thérapeutique » ou un arrêt/une modification des doses. Au cours de cet essai, les utilisatrices ont saisi leurs données et ont reçu en temps réel des recommandations de traitement pour mieux gérer leurs symptômes. Leurs données étaient aussi envoyées simultanément à leur équipe soignante pour que celle-ci puisse suivre l’évolution de leur traitement via un portail Web.

La solution eCO a permis aux prestataires de soins de répondre rapidement aux symptômes rapportés par les patientes, offrant à celles-ci une expérience générale positive. L’analyse de l’enquête a montré que les réponses des patientes concernant l’utilisation de l’application eCO étaient positives et statistiquement significatives. Les patientes ont indiqué que l’utilisation d’eCO leur donnait le sentiment de participer davantage à leurs soins et d’être mieux connectées à leur équipe soignante.

« La publication de ces résultats cliniques positifs dans la revue JCO® Clinical Cancer Informatics suggère qu’il existe un intérêt grandissant pour les solutions digitales d’accompagnement des patients en oncologie » déclare Pierre Leurent, Directeur Général de Voluntis. « Nous concevons des solutions pour aider les personnes atteintes d’un cancer à améliorer la prise en charge des effets secondaires de leur traitement, tout en restant connectées avec leur équipe soignante. Nous sommes certains que les thérapies digitales feront un jour partie des pratiques standards en oncologie clinique. »

AstraZeneca et Voluntis ont conclu un partenariat en 2015, en collaboration avec le National Cancer Institute, pour développer une solution digitale innovante destinée à accompagner les femmes suivant un traitement pour un cancer de l’ovaire platino-sensible récidivant de haut grade dans le cadre d’études cliniques sur l’association thérapeutique cediranib plus olaparib.

A propos de Voluntis

Voluntis développe des thérapies digitales pour aider les patients atteints de maladies chroniques à mieux gérer leur traitement au quotidien afin d’en améliorer l’efficacité. Composées d'applications mobile et web, les solutions de Voluntis délivrent instantanément des recommandations personnalisées au patient et à son équipe soignante afin, par exemple, d'ajuster le dosage d'un traitement, d'en gérer les effets secondaires ou de surveiller des symptômes, tout en permettant un suivi du patient à distance. Ces recommandations sont générées grâce à des algorithmes médicaux digitalisés. Exploitant sa plateforme Theraxium, Voluntis a développé́ des thérapies digitales pour la gestion du diabète, comme Insulia® et Diabeo®, et du cancer, comme Zemy et eCO. Voluntis est partenaire, notamment, de Roche, AstraZeneca, Sanofi et Onduo. Basé à Paris et Boston, Voluntis est membre fondateur de la Digital Therapeutics Alliance. Pour en savoir plus : http : //www.voluntis.com

Diabeo® est une marque déposée de Sanofi. Insulia® est une marque déposée de Voluntis.

IT | 2018-06-27
Teem Photonics appoints Pascal Langlois as new Chairman of the Supervisory Board

June 27, 2018, Meylan, France

Teem Photonics™, the leader in Passively Q-Switched Microlasers as well as Photonics Integrated Circuits based on the ioNext technology, has appointed Pascal Langlois as Chairman of the supervisory board.

With more than 25 years in senior management positions in the industry, Mr. Langlois brings extensive executive experience in leading international businesses with proven track record in corporate transformations as well as of developing, managing and growing international high technology businesses in various industry segments, including automotive, wireless communication, consumer and industrial across the globe.

Most recently, Langlois was President and CEO of Tronics Microsystems a Mems company he has successfully introduced on Euronext Stock market in February 2015 and which was acquired by TDK Group end of 2016. Prior to that he was Chief Sales and Marketing Officer at ST-Ericsson and from 2006, Founder of NXP and part of the executive management team responsible for global commercial operations. He was previously with Philips Semiconductors BV, where he served in various capacities, including Senior Vice President of Sales and Marketing for multimarket products and Vice President/General Manager of the automotive global market segment. He also worked with National Semiconductors, and VLSI Technology, where he was last General Manager of Asia Pacific, Europe & Japan Operations.

“We are delighted to bring onboard as Chairman, someone of the caliber of Pascal Langlois. He has the experience we need to take advantage of the current photonics and laser market opportunities and support Teem Photonics™ to the next level of corporate transformation,” said Antoine Kevorkian CEO and Founder of Teem Photonics™.

“Pascal brings to Teem Photonics™ great experience in the fast-moving technology sector just as the company starts a new venture and expands its businesses. We were fortunate to find someone with his combination of talents to lead the company supervisory board in the next phase of company development,” added Jean Marc Bally Managing Partner at Aster Capital.

“Teem Photonics™ has been very successfully repositioned in the past few years and I look forward to support further developing its next steps and technological leadership, engineering expertise, and manufacturing capabilities,” said Langlois. “The industrial, Life science, Lidar and Datacoms market segments Teem Photonics™ is addressing based on its unique set of technologies are growing very fast and there are numerous opportunities to further grow the company .”

Teem Photonics™ is a privately-held company based near Grenoble, France. Spun off from the GeeO consortium and founded in 1998, Teem Photonics™ is the leader in passively Q-switched microlasers as well as Photonics Integrated Circuits based on ion exchange technology.

Life Science | 2018-06-19
Kuros Biosciences to present promising clinical case studies with MagnetOs at leading spine surgery conference

Schlieren (Zurich), Switzerland, June 19, 2018 Kuros Biosciences will this week present results from several investigator-led clinical case studies of MagnetOs Granules at the 15^thannual State of Spine Surgery Think Tank, a leading conference uniquely dedicated to innovation in spinal surgery.

The case studies, in which MagnetOs Granules were implanted in the spine, were performed by Alwyn Jones MB ChB, BSc, MSc, FRCS, FRSC (Orth), Consultant Orthopaedic Spinal Surgeon at Spire Cardiff Hospital in the UK.

The key clinical outcomes at six months were improved back and leg pain. The most important fusion outcomes were good incorporation of MagnetOs in the posterior fusion bed, graft resorption and remodelling to bone, and progression towards fusion.

Key takeaways from the case studies were:

MagnetOs Granules were well‐tolerated and no device related adverse events were reported in the small cohort of patients requiring spinal fusion
MagnetOs Granules were easy to apply as a stand‐alone graft or when mixed with bone marrow aspirate (BMA) or local bone
Resorption and remodelling of MagnetOs Granules was evident from as early as 3 months post‐implantation
MagnetOs Granules promoted spinal fusion in a mixed cohort of patients when implanted using 5 different surgical approaches

Alwyn Jones said: "I implanted MagnetOs in a cohort of five patients requiring spinal fusion in 2017 and I’m very pleased with their progress. In all cases, my radiographic data indicated remodelling of MagnetOs and progression towards a fusion. All five patients had a reduction in pain, improvement in disability index and improved clinical symptoms compared to their pre-surgical assessment. This initial experience has encouraged me to use MagnetOs in my broader clinical practice."

Joost de Bruijn, Chief Executive Officer of Kuros, said: “The results from these investigator-led clinical case studies with MagnetOs are very gratifying and underline the interest of the clinical research community in our CE marked product. The MagnetOs Granules were easy to apply and showed clear clinical benefits for patients, giving them an improved quality of life with less pain.”

MagnetOs promotes local bone formation equivalent to current gold standard, autograft. MagnetOs is a bone graft substitute intended to fill bony voids or gaps of the human skeletal system and promote the formation of bone at the implanted site. A substantial number of clinically relevant and predictive studies have demonstrated its equivalence to the current gold standard (patient’s own bone, which may not be available in sufficient quantities and/or involves morbidity, costs and pain associated with its harvesting from another healthy site of the patient’s body). MagnetOs is a bone graft comprising biphasic calcium phosphate with an advanced submicron surface topography that directs bone formation after implantation. With its unique submicron surface topography, MagnetOs preferentially directs early wound healing toward the bone-forming pathway, resulting in an osteoinductive claim in Europe. MagnetOs is available as granules and as a putty formulation.

The State of Spine Surgery Think Tank, formerly known as the Cabo Meeting, takes place June 21-13 in Aruba.

For further information, please contact:

Kuros Biosciences AG
Michael Grau
Chief Financial Officer
Tel +41 44 733 47 47
michael.grau@kurosbio.com

Media & Investors
Hans Herklots
LifeSci Advisors
+41 79 598 7149
hherklots@lifesciadvisors.com

About Kuros Biosciences AG

Kuros Biosciences (SIX:KURN) is focused on the development of innovative products for bone regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.

Forward Looking Statements

Life Science | 2018-06-12
Kuros Biosciences announces start of of randomized controlled trial of MagnetOs in spinal fusion

Study should further enhance competitive positioning of MagnetOs

Kuros announced today that the University Medical Center Utrecht (UMCU) in the Netherlands has obtained approval from its ethical committee to start an investigator-led multicenter study comparing MagnetOs with autologous bone in posterolateral spinal fusion.

The study is entitled "A Randomized Controlled Trial of MagnetOs® granules vs. Autograft in Instrumented Posterolateral Spinal Fusion", with UMCU as principal investigator. UMCU’s Department of Orthopedics is one of the foremost orthopedic clinical research centers in the world. The primary objective is to demonstrate non-inferiority with regard to efficacy and safety of MagnetOs compared to the current gold standard, autograft, harvested from the patient’s own body, in instrumented posterolateral spinal fusion. The first patients are expected to be enrolled in H2 2018.

Joost de Bruijn, Chief Executive Officer of Kuros, said: “Spinal fusion is the focus of Kuros’s commercial activity, and this study is expected to generate valuable data to help further differentiate MagnetOs in the bone graft substitute market. It is part of the Kuros philosophy ‘proof what you claim’ and should enhance our competitive positioning.”

Dr. Moyo Kruyt of UMCU, principal investigator of the study said: “We are excited about the prospects of MagnetOs in this study as the solid science underlying MagnetOs has already shown powerful bone generating properties of calcium phosphates with a submicron topography. Replacing patient-own bone with a product like MagnetOs would provide a real clinical benefit.”

Spinal fusion is currently performed by using large amounts of autologous bone graft. A substitute for a patient’s own bone would eliminate the graft harvesting morbidity and associated pain that is one of the main disadvantages of this approach.

About the study

This study is designed as a patient and observer blinded, controlled, randomized, multicenter clinical trial across five centers with intra-patient comparisons. One hundred adult patients qualified for posterolateral spinal fusion in the thoracolumbar and lumbosacral region (T10-S2) will be recruited and enrolled in this study. Primary endpoint is posterior spinal fusion rate after one year based on CT-scans.

For further information, please contact:

Kuros Biosciences AG Media & Investors

Michael Grau Hans Herklots

Chief Financial Officer LifeSci Advisors

Tel +41 44 733 47 47 +41 79 598 7149

michael.grau@kurosbio.com hherklots@lifesciadvisors.com

About Kuros Biosciences AG

Kuros Biosciences (SIX:KURN) is focused on the development of innovative products for bone regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.

Life Science | 2018-06-04
Kuros Biosciences to propose appointment of new Board Members at AGM

Schlieren (Zurich), Switzerland, May 31, 2018 – Kuros Biosciences (SIX: KURN) will propose the appointment of CEO Joost de Bruijn, as well as three new independent non-executive directors at its 2018 Annual General Meeting (AGM) on 14 June.

Shareholder approval will be sought for the appointment of Joost de Bruijn, Chief Executive Officer of Kuros. Dr. de Bruijn has more than 28 years of experience in academia and the life science industry. He was the founder and CEO of Progentix Orthobiology and more recently of Xpand Biotechnology. He is Professor of Biomaterials at Queen Mary University of London, UK, and Professor of Regenerative Medicine and Entrepreneurship at Twente University, The Netherlands.

Jason Hannon, Chief Executive Officer and Member of the Board of Directors of Mainstay Medical SA, is proposed to replace Didier Cowling, who will not stand for reelection. Mr. Hannon has extensive experience in the healthcare and medical devices industry, particularly related to commercialization of new products, penetration of new markets, product innovation, strategic and financial planning, raising capital, regulatory and clinical management, and the building of a high-performance culture. Mr. Hannon previously served as President and Chief Operating Officer of NuVasive (NASDAQ:NUVA), a medical device company focused on the spine market.

Scott P. Bruder, MD, PhD, would replace Frank-Jan van der Velden who will not stand for reelection. Dr. Bruder is an expert in orthobiology and is a seasoned senior executive with a track record spanning more than 25 years at industry leaders such as DePuy Biologics (now Depuy Synthes), Johnson & Johnson Regenerative Therapeutics, LLC, Becton, Dickinson and Company (now BD), and Stryker Corporation.

Oliver Walker would replace Harry Welten who will not stand for reelection. Mr. Walker is a finance executive with more than 20 years of experience covering all aspects of finance including M&A, capital market transactions, treasury, reporting and fundraising. Has was CFO of a number of leading healthcare companies, such as Nobel Biocare, Sonova, and Stratec. Oliver has an MSC in Business Administration & Economics at the University of Berne.

Furthermore, the Board of Directors proposes the re-election of Clemens van Blitterswijk as member, and the election as chairman of the Board of Directors and the re-election of Christian Itin, Leanna Caron, Giacomo Di Nepi and Gerhard Ries as members of the Board of Directors, each for the term until the next Annual Shareholders Meeting.

Documents for the AGM, including the Information Notice with a full agenda, will be made available online on June 1 at: http://www.kuros.ch/investors

For further information, please contact:

Kuros Biosciences AG Media & Investors

Michael Grau LifeSci Advisors

Chief Financial Officer Hans Herklots

Tel +41 44 733 47 47 +41 79 598 7149

michael.grau@kurosbio.com hherklots@lifesciadvisors.com

About Kuros Biosciences AG

Forward Looking Statements This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

Silver Economie | 2018-05-30
Voluntis réussit avec succès son introduction en bourse et lève 30,1 M€ sur le marché réglementé d’Euronext à Paris

 Première introduction en bourse dans le secteur des thérapies digitales en Europe

 Près de 70% de la demande institutionnelle provenant de l’Allemagne, du Royaume-Uni et de la Suède

 Prix de l’offre fixé à 14,0 € par action

 Capitalisation boursière de 105,9 M€

 Titres admis à la cotation le 1er juin 2018

Paris, France, le 29 mai 2018 – 21h45 : Voluntis (la « Société » ou « Voluntis » - mnémonique : VTX - ISIN : FR 0004183960), société spécialisée dans les logiciels thérapeutiques (digital therapeutics), annonce aujourd’hui le succès de son introduction en bourse sur le compartiment C du marché réglementé d’Euronext à Paris.

« Je suis très heureux d’annoncer le succès de notre introduction en bourse sur Euronext Paris, étape structurante dans le développement de Voluntis. Cette opération favorisera notre croissance, notamment aux Etats-Unis où le dispositif commercial sera sensiblement étendu. Elle permet également de consolider notre portefeuille de thérapies digitales, en particulier avec la poursuite du développement de notre solution multi-cancer propriétaire. Ces moyens renforcent notre capacité à déployer à grande échelle des solutions de santé de nouvelle génération qui personnalisent les traitements et accompagnent, au quotidien, le patient dans la gestion de sa maladie » déclare Pierre Leurent, directeur général et co-fondateur de Voluntis. « Nous tenons à remercier nos actionnaires historiques, notre partenaire Sanofi ainsi que nos nouveaux actionnaires pour leur participation à cette levée de fonds. »

L’introduction en bourse, réalisée dans le cadre d’une offre globale (l’« Offre ») comprenant une offre au public en France réalisée sous la forme d’une offre à prix ouvert (« OPO ») et un placement global principalement destiné aux investisseurs institutionnels en France et dans certains pays (« Placement Global »), permet à la Société de lever 30,1 M€ par voie d’augmentation de capital.

Le prix applicable au Placement Global et à l’OPO a été fixé à 14,0 € par action, correspondant au bas de la fourchette indicative de prix resserrée de l’Offre, telle qu’annoncée dans le communiqué de presse de la Société en date du 28 mai 2018.

Sur la base du prix d’introduction de 14,0 € par action, la capitalisation boursière de Voluntis s’élèvera à environ 105,9 M€ à l’issue de l’opération.

Les actions seront tout d’abord négociées sous la forme de promesses d’actions sur le marché réglementé d’Euronext à Paris dès le 30 mai jusqu’au 31 mai 2018 inclus. Elles seront ensuite négociées sur le compartiment C du marché réglementé Euronext Paris sur une ligne de cotation unique intitulée « Voluntis » (code ISIN : FR0004183960 ; code mnémonique : VTX) dès l’ouverture des négociations le 1er juin 2018.

L’option de surallocation n’ayant pas été allouée, il ne sera pas mis en oeuvre d’opération de stabilisation.

Rappel des raisons de l’offre

Le produit net des fonds levés dans le cadre de l’Offre, soit 27,4 M€, sera utilisé selon la répartition suivante :

 à hauteur de 60% afin de renforcer le dispositif commercial du groupe Voluntis en Amérique du Nord et en Europe, via :

o la poursuite de la constitution de l’équipe commerciale, marketing et médicale en charge de la commercialisation directe des logiciels thérapeutiques en diabétologie auprès des organismes payeurs ; et

o la croissance des équipes d’opérations terrain et de support (« field operations »), en charge du soutien au déploiement local des solutions du groupe Voluntis dans les différents pays ciblés,

 à hauteur de 20% afin de poursuivre les développements technologiques, cliniques et réglementaires de la solution multi-cancer propriétaire, en vue de son homologation réglementaire préalablement à sa commercialisation, et

 à hauteur du solde, soit 20%, afin de consolider l’organisation du groupe Voluntis, à travers notamment la croissance de la filiale américaine de la Société et la poursuite des investissements dans la plateforme technologique du groupe Voluntis.

Le produit de l’Offre permettra également à la Société d’accroître sa notoriété en France et à l’international.

Modalités de l’offre

Prix de l’Offre

 Le prix de l’OPO et du Placement Global est fixé à 14,0 € par action.

 Ce prix fait ressortir une capitalisation boursière de Voluntis d’environ 105,9 M€ post augmentation de capital.

Taille de l’Offre et produit brut de l’opération

 2.150.000 actions nouvelles ont été émises dans le cadre de l’OPO et du Placement Global.

 Le produit brut de l’émission s’élève à 30,1 M€.

 Le produit net de l’émission s’élève à environ 27,4 M€.

Répartition des actions souscrites dans le cadre de l’Offre

 Placement Global : 1.991.767 actions nouvelles (soit près de 27,9 M€ et environ 93% du nombre total de titres alloués).

 OPO : 158.233 actions nouvelles au public (soit près de 2,2 M€ et environ 7% du nombre total des titres offerts).

 Dans le cadre de l’OPO, les ordres A1 et A2 seront servis à 100%.

Engagement d’abstention de la Société

A compter de la signature du contrat de placement et de garantie et pendant 180 jours calendaires suivant la date de règlement-livraison, sous réserve de certaines exceptions usuelles.

Engagement de conservation des actionnaires représentant 99,57% du capital social de la Société

A compter de la date du visa de l’AMF sur le prospectus et jusqu’à 360 jours calendaires suivant la date de règlement-livraison des actions de la Société, pour 100% de leurs actions, sous réserve de certaines exceptions usuelles ; étant précisé que cet engagement porte sur l’ensemble des actions de la Société qu’ils détiennent au jour de l’introduction en bourse (mais non celles qu’ils viendraient à détenir, le cas échéant, dans le cadre de ou postérieurement à l’introduction en bourse).

Répartition du capital à l’issue de l’Offre

A la suite de la réalisation de l’augmentation de capital dans le cadre de l’introduction en bourse, le capital social de

Voluntis s’élèvera à 756.766,10 euros, divisé en 7.567.661 actions ordinaires.

Chacun des engagements de souscription tels que décrits dans la note d’opération visée par l’AMF en date du 14 mai 2018 a été servi à hauteur de 100%.

Calendrier de l’opération

30 mai 2018 : Début des négociations des actions de la Société sous la forme de promesses d’actions sur le marché

réglementé d’Euronext à Paris (jusqu’au 31 mai 2018 inclus)

31 mai 2018 : Règlement livraison de l’OPO et du placement global

1 juin 2018 : Début des négociations des actions de la Société sur le marché réglementé d’Euronext à Paris sur une ligne de cotation intitulée « Voluntis »

Codes d’identification des titres Voluntis

 Libellé : Voluntis

 Code ISIN : FR0004183960

 Mnémonique : VTX

 Compartiment : Euronext Paris (Compartiment C)

 Secteur d’activité : 9537 - Software

Intermédiaires financiers / Chefs de File et Teneurs de Livre Associés

BRYAN, GARNIER & CO ODDO BHF

Informations accessibles au public

Des exemplaires du prospectus visé par l’AMF le 14 mai 2018 sous le numéro 18-169, composé du document de base enregistré le 17 avril 2018 sous le numéro I.18-016 et d’une note d’opération (incluant le résumé du prospectus), sont disponibles sans frais et sur simple demande auprès de la société Voluntis, 58 avenue de Wagram, 75017 Paris, France - ainsi que sur les sites Internet de Voluntis (www.voluntis.com) et de l’AMF (www.amf-france.org).

Facteurs de risques

Voluntis attire l’attention des investisseurs sur le chapitre 4 « Facteurs de risques » du document de base enregistré auprès de l’AMF et sur le chapitre 2 « Facteurs de risques liés à l’offre » de la note d’opération et notamment sur son risque de liquidité, la Société estimant être en mesure de faire face à ses engagements jusqu’en septembre 2018 (sans tenir compte du produit net de la présente offre).

À propos de Voluntis

Pour en savoir plus : http : //www.voluntis.com

Diabeo® est une marque déposée de Sanofi. Insulia® est une marque déposée de Voluntis.

Avertissement

Aucune communication, ni aucune information relative à l’émission par Voluntis des actions (les « Actions ») ne peut être diffusée au public dans un pays dans lequel une obligation d’enregistrement ou d’approbation est requise. Aucune démarche n’a été entreprise (ni ne sera entreprise) en dehors de France, dans un quelconque pays dans lequel de telles démarches seraient requises. L’émission ou la souscription des Actions peuvent faire l’objet dans certains pays de restrictions légales ou réglementaires spécifiques. Voluntis n’assume aucune responsabilité au titre d’une violation par une quelconque personne de ces restrictions.

Le présent communiqué ne constitue pas un prospectus au sens de la Directive 2003/71/CE du parlement européen et du conseil du 4 novembre 2003 telle que modifiée, notamment par la Directive 2010/73/UE du Parlement européen et du Conseil du 24 novembre 2010, telle que modifiée et telle que transposée dans chacun des Etats membres de l’Espace Economique Européen (la « Directive Prospectus »).

S’agissant des Etats membres de l’Espace Economique Européen autres que la France (les « États membres ») ayant transposé la Directive Prospectus, aucune action n’a été entreprise et ne sera entreprise à l’effet de permettre une offre au public des titres rendant nécessaire la publication d’un prospectus dans l’un ou l’autre des Etats membres. En conséquence, les Actions peuvent être offertes dans les Etats membres uniquement : (a) à des personnes morales qui sont des investisseurs qualifiés tels que définis dans la Directive Prospectus ; ou (b) dans les autres cas ne nécessitant pas la publication par Voluntis d’un prospectus au titre de l’article 3(2) de la Directive Prospectus.

Pour les besoins du présent paragraphe, la notion d’« offre au public d’Actions » dans chacun des États membres se définit comme toute communication adressée à des personnes, sous quelque forme et par quelque moyen que ce soit, et présentant une information suffisante sur les conditions de l’offre et sur les Actions objet de l’offre, pour permettre à un investisseur de décider d’acheter ou de souscrire ces Actions, telle que cette notion a été, le cas échéant, modifiée dans l’État membre considéré dans le cadre de la transposition de la Directive Prospectus.

Cette restriction de placement s’ajoute aux autres restrictions de placement applicables dans les Etats membres.

La diffusion du présent communiqué n’est pas effectuée par et n’a pas été approuvée par une personne autorisée (« authorised person ») au sens de l’article 21(1) du Financial Services and Markets Act 2000. En conséquence, le présent communiqué est adressé et destiné uniquement (i) aux personnes situées en dehors du Royaume-Uni, (ii) aux professionnels en matière d’investissement au sens de l’article 19(5) du Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (l’« Ordonnance »), (iii) aux personnes visées par l’article 49(2) (a) à (d) (sociétés à capitaux propres élevés, associations non-immatriculées, etc.) de l’Ordonnance ou (iv) à toute autre personne à qui le présent communiqué pourrait être adressé conformément à la loi (les personnes mentionnées aux paragraphes (i), (ii), (iii) et (iv) étant ensemble désignées comme les « Personnes Habilitées »). Les titres sont uniquement destinés aux Personnes Habilitées et toute invitation, offre ou tout contrat relatif à la souscription, l’achat ou l’acquisition des titres ne peut être adressé ou conclu qu’avec des Personnes Habilitées. Toute personne autre qu’une Personne Habilitée doit s’abstenir d’utiliser ou de se fonder sur le présent communiqué et les informations qu’il contient. Le présent communiqué ne constitue pas un prospectus approuvé par la Financial Services Authority ou par toute autre autorité de régulation du Royaume-Uni au sens de la Section 85 du Financial Services and Markets Act 2000.

Le présent communiqué ne constitue pas une offre de valeurs mobilières ou une quelconque sollicitation d’achat ou de souscription de valeurs mobilières ni une quelconque sollicitation de vente de valeurs mobilières aux Etats-Unis. Les valeurs mobilières objet du présent communiqué n’ont pas été et ne seront pas enregistrées au sens du U.S. Securities Act de 1933, tel que modifié (le « U.S. Securities Act ») et ne pourront être offertes ou vendues aux Etats-Unis sans enregistrement ou exemption à l’obligation d’enregistrement en application du U.S. Securities Act. Voluntis n’a pas l’intention d’enregistrer l’offre mentionnée dans le présent communiqué ou une partie de cette offre aux Etats-Unis ni d’effectuer une quelconque offre publique aux Etats-Unis.

La diffusion du présent communiqué dans certains pays peut constituer une violation des dispositions légales en vigueur. Les informations contenues dans le présent communiqué ne constituent pas une offre de valeurs mobilières aux Etats-Unis, au Canada, en Australie ou au Japon.

Le présent communiqué ne doit pas être publié, transmis ou distribué, directement ou indirectement, sur le territoire des Etats-Unis, du Canada, de l’Australie ou du Japon.

Le prospectus visé par l’Autorité des marchés financiers contient des déclarations prospectives. Aucune garantie ne peut être donnée quant à la réalisation de ces déclarations prospectives qui sont soumises à des risques tels que, notamment, ceux décrits dans le prospectus de la Société, et à l’évolution de la conjoncture économique, des marchés financiers et des marchés sur lesquels Voluntis est présente.

Schlieren (Zurich), Switzerland, May 29th , 2018 – Kuros Biosciences (SIX: KURN) announced today the start of an investigator-led study at University Medical Center (UMC) Utrecht, using MagnetOs Granules for maxillary sinus floor elevation with two-stage implant placement. Sinus floor elevation is performed to allow placement of dental implants in the maxilla, or upper jaw. It is most commonly performed when the floor of the sinus is too close to an area where dental implants are to be inserted.

The prospective clinical trial will compare MagnetOs Granules to autologous bone (autograft), harvested from the patient's own body, which is the current gold standard treatment. It is being conducted at the Department of Oral and Maxillofacial Surgery & Special Dentistry, UMC Utrecht and is designed as a controlled open-label, randomized non-inferiority trial with 30 patients. The primary outcome is assessment of effectiveness after 4-6 months. The first patients have already been treated.

Joost de Bruijn, Chief Executive Officer of Kuros, said: “We are very pleased to be taking part in this investigator-led study with the world-renowned Department of Oral and Maxillofacial Surgery at UMC Utrecht. There is a lot of interest from the clinical research community to study a variety of exciting applications in which our CE marked MagnetOs product can promote bone formation. These investigatorled studies expand the clinical evidence base of MagnetOs, and potentially support its positioning in additional therapeutic areas.

” Prof. Toine Rosenberg of the Dept. of Oral and Maxillofacial Surgery at UMC Utrecht, who is leading the study, said: “This is a valuable opportunity to assess promising osteoinductive granules that promote local bone formation, which could help make the delicate task of inserting dental implants easier and more successful. Success in this trial could have implications for multiple other potential applications.”

For further information, please contact: Kuros Biosciences AG Michael Grau Chief Financial Officer Tel +41 44 733 47 47 michael.grau@kurosbio.com Media & Investors Hans Herklots LifeSci Advisors +41 79 598 7149 hherklots@lifesciadvisors.com

About Kuros Biosciences AG

IT | 2018-05-15
Voluntis lance son introduction en bourse sur le marché réglementé d’Euronext à Paris

www.voluntis-finance.com/images/PDF/docs/fr/Voluntis_CP_20180515_Lancement_VF_77223.pdf

Life Science | 2018-05-14
OMNI Appoints Rick Epstein as Chief Executive Officer

RAYNHAM, Mass., May 14, 2018 /PRNewswire/ -- OMNIlife science, Inc. ("OMNI"), a privately-held, established medical technology company targeting the $15 billion global hip and knee replacement device market, reported today that Rick Epstein has joined OMNI as CEO. Before joining OMNI, Mr. Epstein served as President and CEO of Sonoma Orthopedic Products for 5 years. Prior to Sonoma, Rick held several executive leadership positions in prominent organizations including Baxter International and Cardinal Health.

"We are pleased that Rick is joining the OMNI team as our CEO and member of our Board of Directors," commented Guy Mayer, Executive Chairman of OMNI. "Rick's experience successfully leading medical device companies through new product introductions will bring great value as we begin launching our new OMNIBotics® Active Spacer™ technology for robotically balancing the ligaments in a total knee replacement surgery."

"I'm looking forward to leading OMNI through an exciting growth stage as surgeons, hospitals and surgery centers begin to experience the benefits OMNI's products and services will bring to them," Mr. Epstein stated. "The recent FDA clearance of OMNI's Active Spacer along with the OMNIBotics surgical robot and OMNI's knee implants provide surgeons with the most advanced tools available for balancing soft tissue, implanting total knees and ultimately providing the best possible outcomes for their total knee patients."

ABOUT OMNI

OMNI is a privately held company with a proprietary robotic platform, OMNIBotics®, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and enhance a surgeon's ability to help patients live active and pain-free lives. For more information about OMNI, please visit www.omnils.com.

FORWARD LOOKING STATEMENTS

Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms "plans," "believes" or similar expressions are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI's markets, decrease in the demand for OMNI's products, delays in OMNI's product research and development cycles, decreases in the use of OMNI's principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI's current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI's current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI's sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI's products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release.

CONTACT

cindy Holloway, Director of Marketing Communications
Phone: (508) 824-2444
cholloway@omnils.com

Life Science | 2018-05-03
Kuros Biosciences Receives European Clearance for MagnetOs Putty and Prepares for Commercial Roll-Out in the U.S. and Europe

SCHLIEREN (ZURICH), Switzerland, May 02, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) announced today that it has received the CE Mark for MagnetOs Putty indicated for use as an osteoconductive and osteoinductive bone void filler in the skeletal system (i.e. spine, extremities, pelvis, cranium, mandible and maxilla). This market clearance allows commercialization of MagnetOs Putty in Europe, and complements the existing clearance for MagnetOs Granules, and the 510K clearance for both formulations from the U.S. Food and Drug Administration as an autograft extender in the posterolateral spine. With its unique submicron surface topography, MagnetOs preferentially directs early wound healing toward the bone-forming pathway. Numerous studies have shown that MagnetOs leads to progressive bone formation and implant resorption comparable to autograft (patient’s own bone), the current gold standard.

Joost de Bruijn, Chief Executive Officer of Kuros, said: “MagnetOs Putty and MagnetOs Granules have now been cleared in our main target markets. We are gearing up for the commercial roll-out later this year in the U.S. and selected geographies in Europe, as we are executing on our strategy to build a leading orthobiologics company.”

For further information, please contact:
Kuros Biosciences AG
Michael Grau
Chief Financial Officer
Tel +41 44 733 47 47
michael.grau@kurosbio.com

Media & Investors
Hans Herklots
LifeSci Advisors
+41 79 598 7149
hherklots@lifesciadvisors.com

About Kuros Biosciences AG

Kuros Biosciences (SIX:KURN) is focused on the development of innovative products for bone regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.

Forward Looking Statements

Life Science | 2018-04-30
Kuros Biosciences Reports Full-Year 2017 Results

Financial highlights

CHF 17.0 million cash at year-end
CHF 16.9 million equity raise in June 2017
Standby equity facility established in November 2017 to increase financial flexibility

Operational highlights

Successful completion of merger with Xpand Biotechnology creating a leader in orthobiologics
FDA approvals for MagnetOs Granules & Putty
Prepared for U.S. launch of MagnetOs by end of June 2018
Clinical development of Fibrin-PTH for spinal fusion on track

SCHLIEREN (Zurich), Switzerland, April 30, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) reported today its Full-Year 2017 Results, and the publication of its annual report.

2017 has been a transformative year for Kuros Biosciences, which successfully transitioned into a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration. MagnetOs Granules and MagnetOs Putty have been cleared by the U.S. Food and Drug Administration, and the Company is gearing up for their U.S. commercial launch in 2018.

As a technology leader in synthetic and drug-based bone regeneration, Kuros is well-positioned to capture the commercial opportunity in the orthobiologics market, which is estimated to grow to more than $3 billion by 2030. Kuros intends to initially focus on spinal fusion, which represents 50% of the total orthobiologics market.

Joost de Bruijn, Chief Executive Officer, said: “During 2017 we successfully set Kuros on a new course – one that is focused on cutting-edge orthobiologics, an important commercial opportunity. Our international team has responded with verve to our ongoing commercial transition, embracing their new challenges. As a result, we are well-positioned to execute on the commercial roll-out plan for MagnetOs in the U.S. and drive forward our exciting clinical program with Fibrin-PTH in spinal fusion, which represents a huge opportunity.”

Financial position

Cash and cash equivalents (including financial assets and trade and other receivables) as per December 31, 2017, amounted to CHF 17.0 million, compared with CHF 13.0 million as per December 31, 2016. The increase is mainly due to capital increases which off-set net operating cash. In 2017, Kuros received a milestone payment of TCHF 534 (TCHF 997 in 2016) from a collaboration partner. Operating costs for 2017 amounted to CHF 16.8 million, compared with CHF 22.4 million in the previous year. Research and development expenses decreased from CHF 7.9 million in 2016 to CHF 4.5 million in 2017. General and administrative expenses decreased from CHF 17.1 million in 2016 to CHF 15.2 million in 2017.

During 2017, Kuros raised CHF 16.9 million in equity, and put a CHF 30 million equity financing facility in place to provide the Company with more financial flexibility.

Key figures	2017	2016
In TCHF, IFRS
Revenue	534	1,061
Research and development	(4,470)	(7,909)
General and administration	(15,242)	(17,070)
Other income	2,935	2,572
Net operating costs	(16,777)	(22,407)
Operating income/(loss)	(16,243)	(21,346)
Net financial income/(loss)	(350)	1,069
Net income/(loss)	(16,484)	(19,744)
Net income/(loss) per share (in CHF)	(2.32)	(3.95)
Cash and cash equivalents, financial assets And trade and other receivables	17,024	13,034

Outlook
In 2018, the Company aims to capitalize on the restructuring as it executes on its renewed focus on orthobiologics. This includes setting-up a U.S. commercial infrastructure to support the U.S. launch of MagnetOs, as well as the preparation of a Phase 2 clinical study for our drug-based Fibrin-PTH product candidate KUR-113 for spinal indications.

Annual report
The annual report of Kuros Biosciences is available online at
www.kuros.ch/investors/reports-presentations.html.

For further information, please contact:

Kuros Biosciences AG
Michael Grau
Chief Financial Officer
Tel +41 44 733 47 47
michael.grau@kurosbio.com

Media & Investors
Hans Herklots
LifeSci Advisors
+41 79 598 7149
hherklots@lifesciadvisors.com

About Kuros Biosciences AG

IT | 2018-03-28
Résultats semestriels 2017/18 ▪ 9,2% de marge d’EBITDA retraité à taux de change constants ▪ Premiers effets bénéfiques de la réorganisation industrielle au 2nd semestre 2017/18

Confirmation des objectifs du plan de développement : 250 M EUR et 10% de marge d'EBITDA à horizon 2021

Paragon ID (Euronext Paris - FR0011980077 - PID), champion européen des solutions d'identification dédiées aux marchés de l'e.ID, du Transport & Smart Cities, et de la Traçabilité & Protection des marques, publie ses comptes semestriels consolidés condensés de l'exercice 2017/18 (période du 1^er juillet au 31 décembre 2017). Ces comptes ont été approuvés par le Conseil d'administration du 27 mars 2018 et ont fait l'objet d'un examen limité de la part des commissaires aux comptes.

Il est rappelé que le 1^er semestre 2016/17 présente les chiffres historiques de la division Identification de Paragon Group., et à ce titre n'inclut ni les comptes de la filiale Bemrose Booth Paragon qui a rejoint la division au 1^er mars 2017, ni les comptes de Paragon ID et de ses filiales qui sont intégrées au périmètre de consolidation à compter du 1^er mai 2017. Le 1^er semestre 2017/18 est en revanche un semestre où l'intégralité des filiales sont présentes et contributives et constitue, à ce titre, un semestre de référence.

Données consolidées au 31/12 (en M€) – Normes IFRSExamen limité	1^er semestre 2017/18	1^er semestre 2016/17
Chiffre d'affaires	51,6	23,8
EBITDA retraité¹ à taux de change fixes²	4,7	2,3
Marge d'EBITDA retraité¹ à taux de change fixes²	9,2%	9,6%
EBITDA retraité¹	4,3	2,3
Marge d'EBITDA retraité¹	8,3%	9,6%
Dotations aux amortissements et provisions	-2,6	-0,6
Résultat opérationnel courant	1,7	1,7
Marge opérationnelle courante	3,3%	7,2%
Autres produits et charges non courants	-1,7	-0,5
Résultat opérationnel	0,0	1,2
Résultat financier	-1,0	-0,1
Résultat net des activités poursuivies	-1,1	0,9
Résultat net des activités abandonnées	-2,0	-
Résultat net	-3,1	0,9

1 Résultat opérationnel avant amortissements, dépréciations et éléments non récurrents

2 Le retraitement de l'effet change consiste à calculer aux taux de change fixes de 1,18 pour la parité £/€ et de 0,934 pour la parité $/€ l'EBITDA retraité de l'année en cours

Principaux chiffres clés du 1^er semestre 2017/18

Au cours du 1^er semestre de l'exercice 2017/18, Paragon ID a réalisé un chiffre d'affaires consolidé de 51,6 M€, contre 23,8 M€ au 1^er semestre 2016/17 qui n'intégrait pas encore la totalité des filiales. La ligne de business People ID (e.ID, Transport & Smart Cities et Gaming) a totalisé un chiffre d'affaires semestriel de 36,2 M€. L'activité e.ID a connu une baisse cyclique et attendue des livraisons d'inlays du passeport américain, partiellement compensée par l'impulsion des nouveaux pays en Europe et par le fort développement des permis de conduire aux Etats-Unis. En Transport & Smart Cities, le groupe a remporté de nouvelles commandes au cours du semestre (Londres, région Île-de-France, Marseille, Turin) qui commenceront à se matérialiser dans le chiffre d'affaires au 2^nd semestre 2017/18. Le segment Product ID (Traçabilités des produits & Protection des marques) a réalisé un chiffre d'affaires de 15,4 M€.

Le fort développement du marché des Tags RFID (+12% de croissance annuelle moyenne entre 2017 et 2020 / Source : IDTechEx), incite le groupe à renforcer ses investissements commerciaux et marketing sur ce segment. Ainsi, sur le 1^er semestre de l'exercice 2017/18, le regroupement des activités tickets RFID et tags RFID (y compris Gaming) ressort en croissance de +17% par rapport à la même période 2016/17 en pro forma, ce qui représente une performance de 5 points supérieure au marché. L'EBITDA retraité du 1^er semestre 2017/18 ressort à 4,3 M€, soit une marge d'EBITDA retraité de 8,3%, qui n'inclut pas encore le plein effet des mesures de la réorganisation industrielle opérée consécutivement au rapprochement. En outre, l'EBITDA retraité intègre un impact de l'évolution défavorable des parités £/€ et $/€ de -450 K€ sur le semestre. A taux de change fixes, la marge d'EBITDA retraité s'élève à 9,2%.

La rationalisation de l'outil industriel européen du groupe sur les sites d'Argent-sur-Sauldre (France) et de Bucarest (Roumanie) est aujourd'hui achevée. Les deux unités vont désormais bénéficier de la relocalisation en Europe de productions jusqu'alors réalisées en Chine, consécutivement à la fermeture de l'unité de production chinoise au cours du semestre écoulé. Pour rappel, cette réorganisation vise à disposer d'un socle d'efficacité industrielle permettant d'améliorer la compétitivité globale de Paragon ID de l'ordre de 3 M€ en année pleine, à travers des gains de marge et des économies sur les coûts fixes. Cette réorganisation sera pleinement efficiente à compter du mois de juin 2018. Après prise en compte des dotations nettes aux amortissements et dépréciations, le résultat opérationnel courant s'établit à 1,7 M€ au 1^er semestre 2017/18, soit une marge opérationnelle courante de 3,3%. Les autres produits et charges non courants s'élèvent à -1,7 M€, constitués du solde des coûts non récurrents pour la finalisation de la réorganisation industrielle. Le résultat opérationnel ressort à l'équilibre. Le résultat financier s'élève à -1,0 M€, constitué des intérêts des emprunts obligataires. Le résultat net des activités poursuivies est une perte de 1,1 M€, à laquelle s'ajoute 2,0 M€ de perte sur l'activité abandonnée en Chine.

Situation bilancielle au 31 décembre 2017

A l'issue du 1^er semestre 2017/18, les capitaux propres de Paragon ID s'élevaient à 30,9 M€. Les dettes financières s'établissaient à 20,0 M€ à fin 2017, dont 9,8 M€ au titre des découverts et emprunts bancaires, et 8,6 M€ de dettes d'affacturage. Les emprunts auprès des parties liées sont constitués des deux emprunts obligataires souscrit par Paragon Group. (1^er actionnaire à hauteur de 78,4% du capital social de la société). Au 31 décembre 2017, Paragon ID bénéficiait d'une structure financière saine avec une dette financière nette³ s'élevant à 11,2 M€, limitée à 36% des fonds propres.

3 Dettes financières (hors dettes d’affacturage) – trésorerie disponible

Perspectives

A l'issue du 1^er semestre 2017/18, Paragon ID est en phase avec son plan de marche.

La 1^ère moitié de l'exercice a permis de finaliser l'intégration des différentes équipes et l'optimisation des ressources commerciales. Sur le plan des résultats, le niveau d'EBITDA retraité à taux de change fixes est conforme aux objectifs de la société, malgré les perturbations liées à la réorganisation industrielle. Parallèlement, l'assainissement du bilan se poursuit avec notamment une réduction sensible de la dette fournisseurs. Paragon ID est en ordre de marche pour profiter à plein de la dynamique de ses marchés, et confirme donc pleinement les objectifs de son plan de développement : 250 M€ de chiffre d'affaires et 10% de marge d'EBITDA à horizon 2021.

Regroupement des actions Paragon ID le 12 avril 2018

Paragon ID a mis en œuvre, le 12 mars 2018, le regroupement des actions composant son capital social, à raison de 1 action nouvelle contre 35 anciennes. Ce regroupement vise à permettre au groupe de renouer avec un cours de Bourse plus conforme aux standards du marché et aux attentes des investisseurs, tout en tendant à réduire la volatilité du titre. Les opérations de regroupement s'achèveront le 12 avril 2018, premier jour de cotation des nouvelles actions Paragon ID regroupées. A cette date, le capital social sera ainsi composé de 1 665 337 titres et le cours de Bourse théorique post regroupement serait alors de 41,30 €⁴. Le code ISIN des actions nouvelles regroupées sera FR0013318813 ; Cette opération sera sans impact sur la valeur des titres Paragon ID détenus en portefeuille par les actionnaires, exception faite des rompus. En pratique, chaque actionnaire se verra attribuer automatiquement par son intermédiaire financier 1 action nouvelle pour chaque bloc de 35 actions anciennes.

Plus d'informations, sous la forme de « Questions-Réponses », sont disponibles sur le site internet de la société (www.paragon-id.com), dans l'onglet Investisseurs. En cas de questions sur la marche à suivre, les actionnaires ont également la possibilité de contacter la société à l'adresse mail suivante : actionnaires@paragon-id.com.

4 Sur la base du cours de clôture du mercredi 28 mars 2018 (1,18 €)

Agenda financier de l'exercice 2017/18

Publication	Date
Chiffre d'affaires du 3^ème trimestre 2017/18	24 avril 2018
Chiffre d'affaires annuel 2017/18	29 août 2018
Résultats annuels 2017/18	26 octobre 2018

Ces dates sont données à titre indicatif, elles sont susceptibles d'être modifiées si nécessaire. Toutes les publications auront lieu avant l'ouverture des marchés d'Euronext.

A propos de Paragon ID

Issu du rapprochement, fin avril 2017, entre ASK et la division Identification & Traçabilité de Paragon Group Ltd., Paragon ID est un champion des solutions d'identification dédié aux marchés de l'e.ID, du Transport & Smart Cities, et de la Traçabilité & Protection des marques.

Paragon ID offre une large gamme de solutions, embarquées dans tous les types de supports (Passeport, Documents d'identité, Tickets & Etiquettes intelligentes, Smart Cards, Smartphones, Cartes bancaires).

S'appuyant sur plus de 600 collaborateurs à travers le monde, Paragon ID dispose d'une base industrielle forte, avec des usines à proximité de ses clients mondiaux.

Paragon ID est côté sur Euronext Paris. Libellé : Paragon ID - Code ISIN : FR0011980077 - Code mnémonique : PID.

IT | 2018-03-28
RESULTATS ANNUELS 2017

• Accélération de la croissance de l’activité Telecom au second semestre

• Relance de la dynamique commerciale de l’activité Entreprise

• Renforcement de l’organisation commerciale et R&D

• Retour à l’équilibre du résultat net au S2 malgré le contexte d’investissements nécessaires pour accompagner la croissance

Anevia, éditeur de logiciels pour la distribution de la vidéo en direct, en différé et à la demande (VOD), annonce ses résultats de l’exercice 2017, après audit par les Commissaires aux Comptes et validation par le Conseil d’Administration.

French GAAP S1 2017 S2 2017 2017 2016

En M€, au 31/12 6 mois 6 mois 12 mois 12 mois

Chiffre d’affaires 5,3 7,3 12,6 11,7

Marge brute 4,3 5,7 10,0 9,1

En % du CA 81% 78% 80% 78%

Charges d’exploitation (5,4) (6,0) (11,3) (9,6)

En % du CA 102% 82% 90% 82%

Résultat d’exploitation (1,0) (0,2) (1,2) (0,5)

Résultat d’exploitation

(Intégrant le résultat

de change) (1,1) (0,3) (1,4) (0,4)

CIR et subventions 0,4 0,3 0,7 0,6

Résultat net

de la période (0,8) 0,0 (0,7) 0,1

Les frais de R&D sont totalement comptabilisés en charges et sont partiellement financés par le Crédit d’Impôt Recherche (CIR)

ACTIVITÉ DE L’EXERCICE 2017

Sur l’activité Telecom, la performance solide affichée au 1er semestre s’est accélérée au 2 nd semestre avec un chiffre d’affaires qui s’est apprécié sur la période de +53%. Au total, l’activité ressort sur l’année 2017 en hausse de +37% à 9,5 M€. Une performance d’autant plus notable qu’Anevia avait déjà affiché une forte croissance à deux chiffres en 2016 de cette activité.

Sur l’activité Entreprise, Anevia confirme au second semestre une stabilisation de ses revenus par rapport au premier semestre. Le second semestre a été marqué par le recrutement comme VP Sales Worlwide Entreprise d’Ivonne Prugnaud. Ivonne dispose d’une longue expérience de la commercialisation de logiciels et solutions B2B, ayant notamment occupé des fonctions stratégiques au sein du groupe Hoist. Sa compréhension fine des enjeux et des besoins des clients finaux représentera un atout décisif dans le développement de cette activité. Au total en 2017, le chiffre d’affaires d’Anevia s’élève à 12,6 M€, en croissance de 8% par rapport à 2016. Depuis 2014, Anevia affiche une croissance moyenne annuelle (TCAM) de son chiffre d’affaires de +14%. Anevia a d’ailleurs été distingué pour sa trajectoire de croissance enregistrée entre 2013 et 2016 en entrant dans le classement des Champions de la Croissance 2018 publié par Les Echos, auquel ont participé plus de 10 000 entreprises en France.

RESULTATS ANNUELS 2017

Retour à un résultat net à l’équilibre au S2 dans un contexte d’investissements nécessaires pour accompagner la croissance

Afin d’accompagner la dynamique de croissance de l’entreprise et lui permettre de saisir toutes les opportunités d’un marché extrêmement porteur, Anevia a poursuivi le renforcement de son organisation notamment sur les fonctions commerciales et R&D, les deux piliers de son développement. Ainsi, au 31 décembre 2017, les effectifs de la société, incluant les prestataires, atteignaient 94 collaborateurs contre 75 un an plus tôt.

Le Crédit d’Impôt Recherche (CIR) s’élève à 0,7 M€, en hausse par rapport à 2016, illustrant l’embauche de nouveaux ingénieurs R&D.

C’est dans ce contexte d’investissements préparant l’avenir que la société est parvenue à contenir ses charges et à afficher un résultat d’exploitation en amélioration significative au second semestre (-0,2 M€ par rapport au 1er semestre à -1,0 M€), soit au total sur l’exercice -1,2 M€ contre -0,5 M€ en 2016.

Le résultat net revient à l’équilibre au second semestre, contre -0,8 M€ au 1er semestre, et s’établit sur l’ensemble de l’année à -0,7 M€ contre 0,1 M€ en 2016.

Situation de trésorerie au 31 décembre 2017

Au 31 décembre 2017, Anevia disposait d’une trésorerie de 2,3 M€ contre 2,09 M€ au 31 décembre 2016. La trésorerie intègre les fonds levés dans le cadre de l’augmentation de capital avec maintien du DPS qui a été réalisée en février 2017 pour un montant d’environ 1,9 M€ (net de frais). La trésorerie intègre également un prêt de la BPI d’un montant de 0,5 M€ ainsi que le remboursement du CIR 2016 à hauteur de 0,56 M€.

Les dettes financières au 31 décembre 2017 s’élèvent à 3,2 M€ contre 3,0 M€ au 31 décembre 2016.

ACQUISITION DE KEEPIXO

Le 5 mars dernier, Anevia a annoncé l’acquisition de Keepixo, une société spécialisée dans le développement et la commercialisation de logiciels de compression vidéo en temps réel. Située à Grenoble, Keepixo offre aux opérateurs TV des solutions pour une diffusion de leurs vidéos en direct ou en différé, avec faible latence, avec une approche multiécran.

Ce rapprochement stratégique permet à Anevia de créer une offre unique de bout en bout couvrant l’encodage, le packaging, le stockage et le CDN, répondant notamment aux nouvelles exigences de qualité, telle que la haute résolution 4K ou le HDR et renforcer ainsi son positionnement au cœur de la chaîne de valeur OTT vidéo.

La réalisation définitive de l’opération reste soumise à la levée des conditions suspensives usuelles et au vote de l’assemblée générale extraordinaire des actionnaires d’Anevia qui se tiendra, sur première convocation, le 12 avril 2018 au siège de l’entreprise.

R&D : DES PROJETS INNOVANTS POUR RENFORCER NOTRE AVANCE TECHNOLOGIQUE

L’innovation est plus que jamais au cœur du développement d’Anevia. Ses ingénieurs travaillent quotidiennement afin de renforcer l’avance technologique de l’entreprise et apporter aux clients des solutions qui répondent à leurs fortes attentes dans un contexte de transformation profonde de leurs marchés et modèles économiques.

En 2018, Anevia focalisera notamment ses efforts d’innovation autour de trois axes stratégiques majeurs :

• D'une part, les technologies de virtualisation ont considérablement évoluées et permettent aujourd'hui de bénéficier de la simplicité de déploiement, de configuration et d'exploitation sans compromis sur la performance. Au delà du découplage matériel-logiciel, la récente technologie de conteneurisation permet la simplification des tâches d'administration, permettant par exemple à l'aide d'un système d'orchestration de déplacer des logiciels d'une machine à une autre, ou bien de démarrer de plus nombreuses instances de logiciels pour faire face à un pic de charge. L'implémentation de ces technologies (conteneurisation et orchestration) permettra à Anevia d'apporter plus de flexibilité dans le déploiement de ses solutions et d'anticiper sur la transformation actuelle du marché ;

• D'autre part, l'implémentation de nouveaux standards pour répondre à l'attente d'une qualité video toujours meilleure. Dans ce contexte, Anevia fera évoluer ses logiciels pour délivrer une expérience Ultra-HD : augmenter la résolution des videos (4K), améliorer les couleurs et les contrastes (HDR) et fluidifier les mouvements (50Hz) ;

• Enfin, la réduction de la latence introduite par la chaine de diffusion OTT. Regarder en OTT les principaux évènements au plus proche du temps réel est devenu une exigence très forte des utilisateurs, renforcée notamment par l'utilisation des réseaux sociaux pour commenter les contenus télévisés.

Prochaine publication : le 26 juillet 2018, chiffre d’affaires semestriel 2018

A propos d’ANEVIA

Editeur de logiciels pour la distribution de la télévision et de la vidéo en direct, en différé et à la demande (VOD), Anevia fut fondée en 2003 par les créateurs du célèbre VLC Média Player. Véritable pionnière du Cloud DVR et des solutions multiécran, Anevia met au point des technologies innovantes qui permettent de regarder la télévision partout, tout le temps et sur n’importe quel périphérique. Les solutions logiciel Anevia sont utilisées partout dans le monde par les diffuseurs, les opérateurs télécom Tier 1 et Tier 2, ainsi que par de nombreuses entreprises publiques et privées. La société a son siège social en France et dispose de bureaux aux États-Unis et à Dubaï. Anevia est cotée sur le marché d’Euronext Growth à Paris. Pour toute information complémentaire : www.anevia.com.

IT | 2018-03-23
Signature d’une nouvelle commande de cartes Oyster pour Transport for London d’un montant de 2,2 M£

Paragon ID (Euronext Paris - FR0011980077 - PID), champion européen des solutions d’identification dédiées aux marchés de l’e.ID, du Transport & Smart Cities, et de la Traçabilité & Protection des marques, annonce avoir signé auprès de Transport for London, organisme public en charge des transports en commun de la ville de Londres et du Grand Londres (Royaume-Uni), une commande de 2,2 M£ (environ 2,5 M€) pour la fabrication des cartes de transport Oyster tout au long de l’année 2018.

Les cartes Oyster sont des cartes à puce sans-contact, chargées avec des crédits, qui permettent de voyager en métro, en bus, sur les lignes DLR et London Overground (métro aérien), en tramway, avec la compagnie de transports fluviaux MBNA Thames Clippers, et dans la plupart des trains de la National Rail circulant dans Londres. Des millions de trajets sont effectués quotidiennement en utilisant la carte Oyster1 , ce qui en fait l'une des options les plus appréciées par tous ceux qui souhaitent accéder aux transports en commun de la capitale britannique.

Paragon ID est l'une des rares sociétés accréditée ITSO (Integrated Transport Smartcard Organisation), le standard national britannique de Smart Ticketing (billetterie intelligente), et dispose d’usines de fabrication au Royaume-Uni et en Europe.

Le groupe offre une gamme complète de solutions (tickets, magnétiques, tickets sans-contact, cartes sans-contact, services sécurisés, terminaux, applications mobiles, etc.) pour le secteur du transport public, garantissant la sécurité et la fluidité des contrôles d’accès dans des centaines de villes. Paragon ID accompagne ainsi les opérateurs de transport dans le cadre de leur migration progressive du ticket traditionnel, à base de papier, vers des solutions de type Smart Ticket (ticket RFID), Smart Card ou des solutions de billettique embarquée dans un smartphone (type HCE).

Julien Zuccarelli, Directeur général de Paragon ID, déclare :

« Nous sommes très heureux de poursuivre notre relation avec Transport for London et de les compter parmi notre liste croissante de clients dans le secteur des transports en commun. Par ce succès, nous réaffirmons notre position de leader et notre crédibilité sur le marché de la billetterie iintelligente, dont les cartes Oyster constituent l'un des meilleurs exemples technologiques. »

1 Nombre de cartes Oyster utilisées quotidiennement pour voyager : http://content.tfl.gov.uk/daily-breakdown-of-oyster-cardusage-data.pdf

A propos de Paragon ID Issu du rapprochement, fin avril 2017, entre ASK et la division Identification & Traçabilité de Paragon Group Ltd., Paragon ID est un champion des solutions d’identification dédiées aux marchés de l’e.ID, du Transport & Smart Cities, et de la Traçabilité & Protection des marques.

Paragon ID offre une large gamme de solutions, embarquées dans tous les types de supports (Passeports, Documents d'identité, Tickets & Etiquettes intelligentes, Smart Cards, Smartphones, Cartes bancaires).

S’appuyant sur plus de 600 collaborateurs à travers le monde, Paragon ID dispose d’une base industrielle forte, avec des usines à proximité de ses clients mondiaux.

Paragon ID est côté sur Euronext Paris. Libellé : Paragon ID - Code ISIN : FR0011980077 - Code mnémonique : PID. Plus d’informations sur Paragon-id.com

Contacts

Paragon ID ACTUS finance & communication ACTUS finance & communication

Directeur Général Relation investisseurs Relation presse

Julien Zuccarelli Mathieu Omnes Jean-Michel Marmillon

Tél.: +33 (0)4 97 21 48 56 Tél. : +33 (0)1 53 67 36 92 Tél. : +33 (0)1 53 67 36 73

momnes@actus.fr jmmarmillon@actus.fr

IT | 2018-03-05
ANEVIA ACQUIRES VIDEO COMPRESSION EXPERT KEEPIXO SAS

• Creating a turnkey solution for operators and TV broadcasters, covering encoding, transcoding, packaging and storage;

• Expanding in the video encoding market;

• Benefiting from a whole raft of identified operating synergies;

• Acquisition wholly paid for in new ANEVIA shares.

Anevia, a leading provider in OTT and IPTV software solutions, has announced an agreement to acquire 100% of the share capital in French company, Keepixo.

Keepixo is a spin-off of Grenoble-based video coding expert, Allegro DVT, specialising in the development of video compression software for TV operators, to enable live or near-live broadcasts for multi-screen TV. Keepixo’s solutions have been sold to more than 150 clients worldwide, including 40 Tier-1 operators. In 2017, Keepixo recorded sales of €0.9m and had 14 employees, most of whom based in Grenoble.

The acquisition will enable Anevia to offer operators and broadcasters a new, end-to-end encoding, transcoding, storage and packaging solution that will notably comply with new quality standards, such as 4K and HDR.

A whole raft of potential synergies has now been identified as a result of this tie-up, notably including:

• An enhanced product portfolio, adding video compression software to the existing catalogue, with a view to providing a turnkey solution;

• Larger teams, with the addition of 14 new employees, of which 10 engineers sharing a similar software architecture design and company culture to those of Anevia;

• Increased market potential, with: - A comprehensive and competitive solution with which to address the Tier-2 and Tier-3 operators market, in which cost concerns take precedence over so-called ‘Best of Breed’ technologies; - The development of a transcoding solution for local network headends for the enterprises market;

• Combined technological expertise, allowing the two companies to:

- Share technical skills, notably in packaging and low latency broadcasting technologies;

- Pooling Keepixo’s expertise in audio/video compression (HEVC, 4K and HDR) and low latency packaging with that of Anevia in network architecture and video solution integration;

- Sharing Quality Assurance methods and processes; - Combining R&D resources;

- Sharing project and support/operations-related resources.

The acquisition is to be fully funded via an exchange of shares, in which new Anevia shares will be issued and exchanged for Keepixo shares under an in-kind contribution agreement.

-Ends-

Notes to Editors:

TERMS OF THE TRANSACTION

Anevia’s Executive Board having approved the transaction, a Contribution and Exchange Agreement was subsequently signed between Anevia and Keepixo shareholders. Serge Godard was appointed shares auditor and tasked with writing a report on the value of the in-kind contribution and on the remuneration of the shares contributed (and on the equitable nature of the exchange ratio).

Under the Contribution and Exchange agreement, the in-kind contribution from Keepixo is to be remunerated via the issuance of 307,200 new Anevia shares at a unit price of €2.63**, consisting of a par value of €0.05 and a contribution premium of €2.58 per unit, thereby valuing Keepixo at €807,936.

Final completion of the transaction will be subject to the removal of all the usual conditions precedent and to the shareholders’ vote at the Extraordinary General Meeting, which has been convened, on first notice, on April 12, 2018.

The new shares will be subject to a request for admission to trading on the Euronext Growth market in Paris, under the same ticker as existing Anevia shares. Subject to the AGM’s approval of the in-kind contribution, and as a result of the transaction, Anevia’s share capital will come to €192,979.60 divided into 3,859,592 shares. The 307,200 new Anevia shares will therefore account for 7.96% of Anevia’s share capital and 5.77% of its voting rights.

Provisional acquisition timetable

Notice of the meeting published in BALO (French Mandatory Legal Notices Bulletin) 3/7/2018

Convening notice of EGM 3/26/2018

Extraordinary General Meeting 4/12/2018

Settlement and delivery of new shares 4/16/2018

** This figure equates to the average price of Anevia shares over the 20 trading sessions prior to December 4, 2017, the date on which the parties decided on the acquisition price.

Impact on current shareholders’ equity

The issuance of 307,200 new Anevia shares would have the following impact on shareholders owning 1%, 5% and 10% of the Company’s share capital prior to the agreement (calculation based on the number of shares comprising the company’s share capital on the date of this press release):

Share of equity (%)

Prior to the issue of 307,200 new shares ............................10 % 5 % 1 %

Subsequent to the issue of 307,200 new shares ................. 9.20 % 4.60 % 0.92 %

About ANEVIA

Anevia is a leading OTT and IPTV software vendor that specialises in delivering innovative solutions for live TV, near-live, video on demand (VOD) and multi-screen. Anevia was founded in 2003 by the developers of the well-known VLC media player, and since then the company has pioneered unique solutions across several fields, including cloud DVR and multi-screen. Anevia’s mission is to deliver innovative technologies that enable viewers to enjoy a next-generation TV experience – wherever, whenever and on every screen. Anevia’s solutions have been adopted by globally-renowned TV broadcasters, telecommunication and pay-TV operators, video service providers and many private and public companies. Anevia is headquartered in France, with regional offices in the USA and Dubai. Anevia is listed on the Paris Euronext Growth market. For more information please visit www.anevia.com.

About KEEPIXO

Video compression expert Keepixo develops and sells software solutions for distributing audiovisual content in IPTV and OTT (over-the-top) mode. Keepixo’s solutions enable video compression and the conversion of audio/video data into the formats and protocols required for Internet routing in IPTV and OTT TV mode (OTT packaging). Keepixo offers a broad range of products, including video encoders and transcoders for live and VOD broadcasting, mosaic TV channel generators and live-to-VOD recording solutions for catch-up TV services. For more information please visit www.keepixo.com.

Contacts

ANEVIA ACTIFIN

Sabine de Leissègues Alexandre Commerot

Marketing & Communications Director Isabelle Dray (press relations)

Tel: +33 1 81 94 50 95 Tel: +33 1 56 88 11 11

Email: investisseurs@anevia.com Email: acommerot/idray@actifin.fr

Name: ANEVIA

ISIN Code: FR0011910652

Ticker symbol: ALANV

Number of shares comprising the share capital: 3,551,218

DISCLAIMER

This press release contains non-factual information including, notably but not exclusively, some forward-looking statements about future results and other planned events. These statements are based on the current outlook taken, and assumptions made, by the Company’s management. These take into account both known and unknown risks and uncertainties that could potentially lead to significant differences in terms of earnings, profitability and planned events. Furthermore, the accuracy of the statistics and provisional information provided by, or derived from, industry publications or third party sources and contained in this press release has neither been verified, nor is the subject of any announcements or guarantees made, by Anevia or its shareholders and affiliates, directors, executives and advisors, or employees: such provisional statistics and information are included in this press release for information purposes only. Finally, the present press release may be drafted in French and English. In the event of discrepancies between the two publications, the French-language version shall take precedence.

Smartphones are increasingly delivering verified treatments for diabetes, addictions and ADHD

LUANN STOTTLEMYER has had diabetes for 23 years, but it was only in 2016 that her doctor prescribed a treatment that changed her life. It has allowed her to bring her blood-sugar levels under control and lose weight. Yet this miracle of modern science is not a new pill. It is a smartphone app called BlueStar.

The program is one of a growing number of apps that America’s Food and Drug Administration (FDA) has approved to treat everything from diabetes to substance abuse. The FDA has encouraged firms to join a scheme that aims to streamline the regulatory process for such treatments. There are many candidates: at least 150 firms globally are developing some form of “digital therapeutic” (“digiceutical” in the lingo), says Mark Sluijs, who advises Merck, a big American drugmaker.

Unlike other sorts of digital health apps, digiceuticals have been tested for efficacy, approved by regulatory agencies such as the FDA and are prescribed by a doctor. Most gather data, either by asking patients for information or by using sensors, and provide real-time guidance. Diabetes apps, for instance, work with connected monitors and use the information to manage symptoms. Apps that help users to stop smoking combine a breath sensor with coaching on how to quit. Addiction-fighting apps can be based on cognitive behavioural therapy.

Most apps are developed by startups, many of which are based in and around Boston. One such, Pear Therapeutics, has a pipeline of treatments at various stages of development, much like a conventional pharmaceutical firm. These apps are aimed at treating a range of conditions: opioid addiction, schizophrenia, anxiety, insomnia, post-traumatic stress disorder (PTSD), depression and chronic pain. Pear’s reSET app, for instance, which treats disorders involving the misuse of alcohol, cocaine and other stimulants, has been approved for sale and should be on the market in early 2018. The app will be more effective than conventional treatments, claims Corey McCann, Pear’s chief executive. It carefully trains patients to recognise daily triggers and cravings and to monitor and track these with their doctor.

Another area of attention is medication for attention-deficit hyperactivity disorder (ADHD), on which Americans spend $14bn annually. Akili Interactive, another startup, recently completed a trial showing that a computer game it has developed to treat ADHD can improve attention and inhibitory control in children. If approved, the game would be the first digital therapeutic for this disease. As well as competing with existing drugs, it may also appeal to parents who are reluctant to medicate their children for ADHD.

Some digiceuticals will work better alongside conventional drugs, rather than on their own—opening up possibilities for alliances between tech and pharma firms. Voluntis, a startup, develops companion software for specific medications or medical devices. These programs can monitor side-effects, help manage symptoms and connect patients with doctors and nurses.

Pharma firms and venture capitalists remain cautious, however. Only a few drugmakers have invested in startups, and VCs are waiting to see what happens with the current crop of businesses, says Nikhil Krishnan of CB Insights, a data provider. One reason for the reluctance is a lack of rules for prescribing and paying for these apps—a problem that a new lobbying group, the Digital Therapeutics Alliance, wants to tackle. Cultural hurdles have to be overcome, too: many patients will find it hard to believe that software can be as effective as a pill. Analysts estimate that the market for digiceuticals will be worth a modest $9bn by 2025.

Once accepted, however, digiceuticals should take off and may well be created by large pharma and tech firms as well. The apps make it possible both to measure whether patients are adhering to their treatment, and to collect evidence on outcomes. Barriers to entry for startups are lower than for drugmakers, which need access to costly laboratories and manufacturing facilities. So many apps will compete to treat the same disease, which should spark very rapid innovation—a rare phenomenon in medicine—and perhaps even to lower prices, a rarer one still.

Life Science | 2018-02-06
New Data and Surgical Experiences with OMNIBotics® Active Spacer™ Ligament Balancing System Presented at Prestigious Orthopaedics Conference

Clinical Evaluators Share Positive Results of Revolutionary Technology that Combines the Precision of Robotic-Assisted Bone Cutting with Dynamic Real-Time Soft Tissue Management

(Raynham, MA February 5, 2018) OMNIlife science™, Inc. ("OMNI™"), an established medical technology company targeting the $15 billion global hip and knee replacement device market, announced that several presentations about their breakthrough OMNIBotics Active Spacer technology were featured at the International Congress for Joint Reconstruction (ICJR) 10^th Annual Hip & Knee Conference held in Vail, CO from January 18-21.

The ICJR focuses on providing a comprehensive orthopaedic learning experience for their members, delivering timely and relevant education. The more than 150 attendees learned about OMNIBotics Active Spacer technology in both a pre-recorded surgery presentation and a podium presentation. The surgery, “TKA Utilizing OMNIBotics Active Spacer Robotically Assisted Ligament Balancing System” was performed and narrated by Jeffrey H. DeClaire, MD, DeClaire LaMacchia Orthopaedic Institute, Rochester Hills, MI. The podium presentation “Ligament Balancing Technology in TKA” was given by John Keggi, M.D., Connecticut Joint Replacement Institute, Hartford, CT.

Dr. DeClaire commented, “With this new technology and the ability to capture accurate data, the Active Spacer can help to more accurately and consistently restore the normal soft tissue balance of the knee with the potential to improve patient outcomes and patient satisfaction.”

The OMNIBotics Active Spacer, with more than 150 procedures performed to date, provides the surgeon with a quantitative tool to actively manage the soft tissue envelope with dynamic real-time feedback. Since sub-optimal soft tissue balancing is a potential contributing factor to patient dissatisfaction with their knee replacement, OMNI developed this device to address that need. When the OMNIBotics Active Spacer is combined with the accuracy of alignment and bone cuts provided by the OMNIBotics system, the result is a completely customized procedure from both a skeletal and a soft tissue perspective.

“The Active Spacer provides the most accurate and useful information to date for achieving good balance in knee replacement patients,” stated Dr. Keggi. “Surgeons can now see the full motion and precise balance of the knee in real time, which provides important feedback to optimize the function of the knee.”

he OMNIBotics Active Spacer received FDA clearance in early September, 2017 and is currently in clinical evaluation at six sites in the United States and one in Australia.

About OMNI

OMNI is a privately held company with a proprietary robotic platform, OMNIBotics®, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and enhance a surgeon’s ability to help patients live active and pain-free lives. For more information about OMNI, please visit www.omnils.com.

Forward-Looking Statements

Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms “plans,” “believes” or similar expressions are “forward‐looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward‐looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI’s markets, decrease in the demand for OMNI’s products, delays in OMNI’s product research and development cycles, decreases in the use of OMNI’s principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI’s current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI’s current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI’s sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI’s products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release

Contact

Cindy Holloway, Director of Marketing Communications

Phone: (508) 824‐2444

cholloway@omnils.com

IT | 2018-01-15
Un changement de dimension réussi en 2017 : chiffres d’affaires annuel consolidé de 34,31 M€ en croissance totale de 89%

PARIS, le 15 janvier 2018 - EKINOPS (Euronext Paris - FR0011466069 – EKI), fournisseur leader de solutions de télécommunications dédiées aux opérateurs de télécommunications, publie son chiffre d’affaires consolidé au titre de l’exercice 2017, clos le 31 décembre 2017. La société OneAccess est consolidée par intégration globale depuis le 1er octobre 2017 dans les comptes du groupe.

En M€ - Données consolidées non auditées 2017 2018 Variation

Chiffres d’affaires 34,31 18,18 +89%

Sur l’exercice 2017, le chiffre d’affaires consolidé d’Ekinops s’est établi à 34,31 M€, en croissance de +89%. « Nous sommes très fiers d’avoir pu intégrer l’équipe talentueuse de OneAccess au 4ème trimestre et l’accueil de ce rapprochement par nos clients opérateurs est excellent » commente Didier Brédy, Président-Directeur général d’Ekinops. « Nous nous sommes réorganisés pour être en mesure de livrer de la croissance en tirant parti de nos solutions innovantes et de notre portefeuille clients riche en opérateurs de rang 1.

Une année 2017 marquée par des succès stratégiques, commerciaux et technologiques

L’année 2017 marque un véritable changement de dimension pour le groupe à travers le rapprochement stratégique avec OneAccess. Cette opération a permis de donner naissance à un acteur de référence des solutions pour les réseaux télécom, présent à la fois sur les solutions de transport optique, les services Ethernet et de routage d’entreprise.

La vision technologique commune des deux sociétés, avec une forte culture logicielle, et leur très grande complémentarité produits, allant de la couche transport des réseaux (couche 1) aux besoins en matière de routage et de services Ethernet et IP (couches 2 et 3), vont permettre au groupe désormais constitué de pénétrer de nouveaux segments de marché et de générer de la croissance dans un marché où le trafic Internet ne cesse d’augmenter et les besoins des opérateurs sont croissants.

En matière de transport optique, l’année 2017 a été marquée par le succès commercial des solutions 100G & 200G et la mise sur le marché, en fin d’année, d’un nouveau module optique 100G / 200G de nouvelle génération, doté d’une taille réduite, permettant de diviser par deux la consommation électrique et de diminuer sensiblement le coût du transport des données sur les réseaux optiques.

En matière de routage et de virtualisation des réseaux, le lancement du nouveau système d'exploitation OneOS6 constitue la principale évolution technologique de l’année écoulée. OneOS6 offre aux opérateurs la possibilité de prendre le contrôle de leur migration vers des services virtualisés à l'aide de solutions complètes, flexibles et totalement indépendantes des fournisseurs d’équipements.

Activité de la filiale OneAccess

Le groupe a bénéficié de la consolidation de la société OneAccess à compter du 4ème trimestre 2017, à hauteur de 15,24 M€ sur la période. Sur l’exercice 2017, la zone EMEA (Europe, Moyen-Orient & Afrique) a représenté 86% de l’activité de la nouvelle filiale, la région APAC (Asie-Pacifique) 10% et les Amériques 4%.

Sur le plan commercial, OneAccess compte cinq opérateurs de rang 1 (Tier 1) au sein de son Top 10 clients 2017.

Activité du périmètre historique d’Ekinops

Sur le périmètre historique d’Ekinops (hors OneAccess), la croissance annuelle s’est établie à +5% par rapport à 2016 (+6% à taux de change constants).

Le ralentissement de la croissance au 4ème trimestre est la conséquence du décalage du cycle d’investissement du 1er client d’Ekinops en 2016. Hors impact de ce décalage de commandes avec ce client basé dans la zone EMEA Nord, la croissance annuelle d’Ekinops s’est établie à +14% en 2017.

La croissance annuelle a été portée par la progression des ventes de solutions 100G & 200G, en hausse de +18% sur l’ensemble de l’exercice. Cette ligne business a représenté 71% de l’activité en 2017 (vs. 61% en 2016). Les activités de services ont pour leur part progressé de +14% sur l’année (représentant 11% du chiffre d’affaires total). Enfin, les ventes d’équipements 10G ont poursuivi leur recul programmé (-30%), et ne représentaient plus désormais que 18% de l’activité (vs. 26% en 2016).

Sur le plan géographique, les Etats-Unis sont demeurés la 1ère zone de facturation d’Ekinops en 2017, représentant 40% du chiffre d’affaires, poids stable par rapport à 2016. Avec 31% des facturations totale (38% en 2016), EMEA Nord est restée la 2ème zone géographique en 2017 malgré l’impact du décalage de commandes sur 2018 du 1er client. L’Europe de l’Est a enregistré une activité dynamique, totalisant 23% de l’activité de l’année (vs. 12% en 2016). Enfin, EMEA Sud a représenté 6% des facturations en 2017, contre 10% un an plus tôt.

Agenda financier 2018

Ekinops annonce son agenda de publications financières au titre de l’exercice 2018. Toutes les publications interviendront après la clôture du marché d’Euronext Paris.

A propos d’EKINOPS

Ekinops est un fournisseur leader de solutions de télécommunications, ouvertes et interopérables, destinées aux fournisseurs de services (opérateurs de télécommunications et entreprises) à travers le monde.

Les solutions Ekinops, hautement programmables et évolutives, permettent le déploiement rapide et de manière flexible de nouveaux services de transport optique, haut débit et haute vitesse, ainsi que des services d'entreprise, notamment à travers la virtualisation des réseaux. Le portefeuille de solutions se compose de deux ensembles de produits parfaitement complémentaires :

▪ la plateforme Ekinops 360, afin de répondre aux besoins des réseaux métropolitains, régionaux et longue distance, à partir d’une architecture simple et très intégrée, pour la couche 1 (transport) des réseaux ;

▪ les solutions OneAccess, afin de proposer un large choix d'options de déploiement, physiques et virtualisées, pour les couches 2 et 3 (liaison et réseau).

À mesure que les fournisseurs de services adoptent les modèles de déploiement SDN (Software Defined Networking) et NFV (Network Functions Virtualization), les solutions Ekinops leur permettent ainsi de migrer, de manière transparente, vers des architectures ouvertes et virtualisées.

Ekinops dispose d’une organisation mondiale qui lui permet d’opérer sur les 4 continents. Ekinops est coté sur Euronext à Paris.

Libellé : Ekinops

Code ISIN : FR0011466069

Code mnémonique : EKI

Nombre d’actions composant le capital social : 21 242 747

Plus d’informations sur www.ekinops.net

Contact INVESTISSEURS

Mathieu Omnes

Relation investisseurs

Tél. : +33 (0)1 53 67 36 92

momnes@actus.fr

Contact EKINOPS

Dominique Arestan

Directeur Communication

Tél: +33 (0)1 77 71 13 20

darestan@ekinops.net

Contact PRESSE

Nicolas Bouchez

Relation presse

Tél. : +33 (0)1 53 67 36 74

nbouchez@actus.fr

Silver Economie | 2018-01-09
Voluntis and WellDoc Announce Partnership to Combine Diabetes Digital Therapeutic Offerings

Cambridge, MA, and Columbia, MD, 09 january 2018

Voluntis and WellDoc®, two of the industry’s leading digital therapeutics companies, announced today a commercial agreement aimed at combining Voluntis’ insulin titration technology with WellDoc’s extensive digital coaching platform to create a holistic digital diabetes management solution for patients, providers, health systems and health plans.

Voluntis developed Insulia®, an FDA-cleared, prescription-only digital companion for people and their care teams using basal insulin to treat type 2 diabetes. It provides automated basal insulin dose recommendations for people with type 2 diabetes while enabling the health care team to remotely monitor progress.

The developer of BlueStar® – an FDA-cleared, digital therapeutic for individuals with type 2 diabetes – WellDoc is the first digital health company in the US to conduct randomized clinical trials that demonstrate significant clinical outcomes, as published in multiple peerreviewed journals and presented at leading industry conferences. The clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for individuals living with type 2 diabetes who used BlueStar1. BlueStar provides real-time and timely individualized coaching and support, as well as educational tools that are actionable and personal for individuals living with type 2 diabetes.

“We are excited to be working with WellDoc so that we can bring together extensive coaching and actionable insulin titration recommendations,” said Voluntis Chief Executive Officer Pierre Leurent. “By bringing both products and these capabilities under the same umbrella, we hope to further simplify treatment for people living with type 2 diabetes.”

The pioneering companies maintain a shared vision of how digital technologies can positively impact the health of patients. In order to realize this goal, Voluntis and WellDoc are committed to clinical validation of their solutions, rigorous adherence to regulatory requirements, working with stakeholders to drive utilization and reimbursement, and collaboration with industry partners that complement each company’s respective solutions.

“We are pleased to announce this significant commercial agreement with Voluntis and believe that our two organizations greatly complement each other,” said WellDoc President and CEO Kevin McRaith. “Together, we will be able to provide a combined solution that providers, health systems, and health plans can offer to their members with type 2 diabetes.”

Efforts are already underway to implement a combined product offering, which will be rolled out through a phased approach. The companies expect to begin joint discussions with stakeholders (i.e., health systems and health plans) as early as late-Q1 2018 to convey the advantages and value of the combined product offering as enabled by the Voluntis-WellDoc commercial agreement.

About WellDoc®

WellDoc® is a leading digital health company revolutionizing chronic disease management to help transform lives. Our groundbreaking technology is guiding individuals through the complicated journey of living with chronic diseases, with a goal of improving their health and helping them to be more balanced. We are the first digital health company based on a life science business model with a foundation that is built on randomized clinical trials that demonstrate significant clinical outcomes. We have mastered diabetes management by taking an aggressive and innovative approach that utilizes sophisticated logic and precise algorithms, and integrates the most advanced mobile technology, behavioral insight, and diabetes education for those living with type 2 diabetes.

Our FDA-cleared, proven digital therapeutic, BlueStar®, provides real-time and timely individualized coaching and support, as well as diabetes educational tools that are actionable and personal. Our clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar®. In November 2017, the IQVIA Institute for Human Data Science (formerly Quintiles/IMS) named BlueStar the “top app” in clinical diabetes treatment. For more information, visit www.welldoc.com.

About Voluntis

Voluntis creates digital companions that empower people to self-manage their treatment in remote collaboration with their health care teams. Dedicated to chronic conditions, Voluntis’ products aim to personalize treatment, support team-care coordination and improve real-world outcomes. Voluntis leverages its expertise in digitizing clinical algorithms and its technology platform to design its companion solutions. These include Insulia and Diabeo in diabetes as well as eCO and Zemy in oncology. Voluntis has long-standing partnerships with leading life science companies such as Sanofi, Roche and AstraZeneca. It is a founding member of the Digital Therapeutics Alliance. For more information, visit http://www.voluntis.com/.

Media Contact for WellDoc:

Juliette Bogus

PressComm PR for WellDoc

Email: juliettebogus@presscommpr.com

[1] Quinn CC, et al. Diabetes TechnolTher.2008 ;10(3) :160-168. Quinn CC, et al. Diabetes Care. 2011: 34(9): 1934-1942.

Richard Katz, MD; George Washington University Medical Center; Journal of Health Communication, December 2011.

Quinn, CC, et al. Glycemic Control: Impact on Physician Prescribing Behavior, Presentation ADA 72ndScientific Sessions, 2012.

Tang PY, et al. "eHealth-Assisted Lay Health Coaching for Diabetes Self-Management Support." American Diabetes Association 76th Scientific Sessions Poster Presentation 2016 presented at AADE San Diego 2016.

CONTACT

Amélie Janson

Voluntis

press@voluntis.com

+33 1 80 03 19 52

Life Science | 2018-01-08
Kuros Biosciences Expands License Agreement with Checkmate

Schlieren (Zurich), Switzerland, January 8, 2018 – Kuros Biosciences (SIX: KURN) announced today that it has amended its exclusive license agreement, which was originally signed in 2015, that grants Checkmate Pharmaceuticals Inc., Cambridge, MA, USA (“Checkmate”) access to Kuros’ clinically validated product candidate CYT003 as well as its VLP platform and to technology related to oligonucleotide synthesis.

The amendment extends the field from oncology to all indications and broadens the range of product candidates covered. In exchange for the amendment of the license, Kuros receives an upfront payment

“We are excited about the amendment of the existing agreement with Checkmate and continue to believe that Checkmate is well positioned to advance treatment options for patients”, commented Joost de Bruijn, CEO of Kuros. “The Checkmate team is pleased to obtain these rights to Kuros’ VLP platform, which we believe has a great deal of potential for further clinical development”, affirmed Art Krieg, CEO of Checkmate.

For further information, please contact:

Joost de Bruijn

Chief Executive Officer

Tel +31 6 21 21 76 03

Joost.de.bruijn@kurosbio.com

About Kuros Biosciences AG

Forward Looking Statements

Last News

2018-09-20
Voluntis – First-half 2018: expanded and strengthened abilities to pursue future growth

2018-09-14
Kuros Biosciences to Host Key Opinion Leader Meeting on Establishing the New Gold Standard in Bone Regeneration

2018-09-05
Kuros Biosciences Reports Results for First Half 2018

2018-08-23
Kuros Biosciences appoints Pascal Longlade as Chief Medical Officer

2018-08-16
Voluntis releases upgraded version of Insulia to improve user experience, including Spanish

2018-07-31
Voluntis announces the launch of Theraxium Oncology, an innovative digital platform for symptom management

2018-07-16
Publication des résultats de l’étude eCO dans la revue JCO® Clinical Cancer Informatics

2018-06-27
Teem Photonics appoints Pascal Langlois as new Chairman of the Supervisory Board

2018-06-19
Kuros Biosciences to present promising clinical case studies with MagnetOs at leading spine surgery conference

2018-06-12
Kuros Biosciences announces start of of randomized controlled trial of MagnetOs in spinal fusion

2018-06-04
Kuros Biosciences to propose appointment of new Board Members at AGM

2018-05-30
Voluntis réussit avec succès son introduction en bourse et lève 30,1 M€ sur le marché réglementé d’Euronext à Paris

2018-05-30
Kuros Biosciences announces start of investigator-led study of MagnetOs Granules for maxillary sinus floor elevation

2018-05-15
Voluntis lance son introduction en bourse sur le marché réglementé d’Euronext à Paris

2018-05-14
OMNI Appoints Rick Epstein as Chief Executive Officer

2018-05-03
Kuros Biosciences Receives European Clearance for MagnetOs Putty and Prepares for Commercial Roll-Out in the U.S. and Europe

2018-04-30
Kuros Biosciences Reports Full-Year 2017 Results

2018-03-28
Résultats semestriels 2017/18 ▪ 9,2% de marge d’EBITDA retraité à taux de change constants ▪ Premiers effets bénéfiques de la réorganisation industrielle au 2nd semestre 2017/18

2018-03-28
RESULTATS ANNUELS 2017

2018-03-23
Signature d’une nouvelle commande de cartes Oyster pour Transport for London d’un montant de 2,2 M£

2018-03-05
ANEVIA ACQUIRES VIDEO COMPRESSION EXPERT KEEPIXO SAS

2018-02-07
A new sort of health app can do the job of drugs

2018-02-06
New Data and Surgical Experiences with OMNIBotics® Active Spacer™ Ligament Balancing System Presented at Prestigious Orthopaedics Conference

2018-01-15
Un changement de dimension réussi en 2017 : chiffres d’affaires annuel consolidé de 34,31 M€ en croissance totale de 89%

2018-01-09
Voluntis and WellDoc Announce Partnership to Combine Diabetes Digital Therapeutic Offerings

2018-01-08
Kuros Biosciences Expands License Agreement with Checkmate